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Abstract 
Given their biological properties, Mesenchymal Stem Cells (MSCs) 
represent a potentially precious therapeutic tool for clinical application. 
However, their optimal use depends on our understanding of the 
molecular mechanisms governing their expansion and differentiation, still 
poorly understood.  
The kinase receptor Kit and the transcription factor Prep1 are pleiotropic 
regulators playing key roles in development and differentiation of 
multiple tissues, including hematopoiesis. 
The aim of my study is to investigate whether Kit and Prep1 contribute 
also to the control of MSCs, particularly in their commitment and 
differentiation towards the osteogenic and the adipogenic lineages, as 
MSCs and their progeny, in particular osteoblasts, are essential 
components of the hematopoietic stem cell niche. 
As a first step, the expression profiles at the transcriptional and protein 
level were analyzed in undifferentiated MSCs, and during in vitro 
osteogenic and adipogenic differentiation. Subsequently, to gain insights 
into Prep1 function in mesenchymal cells, the effects of its in vivo 
downregulation were investigated by using hypomorphic mice exhibiting 
low levels of Prep1 product.  
The expression studies have shown that Kit and Prep1 are both expressed 
in undifferentiated MSCs and that their activity is inversely correlated 
during the adipogenic process. Furthermore, analysis of MSCs derived 
from a Kit/GFP transgenic mouse line indicates that regulatory elements 
that drive correct kit expression in hematopoietic, germ and cardiac cells 
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are not sufficient to control kit activity in MSCs. In addition, the 
functional studies demonstrate that down-regulation of Prep1, while 
favouring in vitro adipogenesis, strongly compromise the osteogenic 
process, leading cells to apoptosis after osteogenic induction.  
Taken together, results indicate that Kit and Prep1 are involved in the 
regulation of murine MSCs, and provide the first evidence pointing to 
Prep1 as a crucial player in mesenchymal cell fate decisions. 
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INTRODUCTION	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1. Stem Cells 
 Stem cells are distinguished from other cell types by two important 
characteristics. First, they are unspecialized cells capable of renewing 
themselves through cell division, sometimes after long periods of 
inactivity. Second, under certain physiologic or experimental conditions, 
they can be induced to become tissue- or organ-specific cells with special 
functions. In some organs, such as the gut and bone marrow, stem cells 
regularly divide to replace cells for the normal turn over and repair 
damaged tissues. In other organs, however, such as the pancreas and the 
heart, stem cells only divide under special conditions. 
According to their developmental potential, stem cells can be classified in 
different types. Embryonic stem cells are pluripotent cells as they have 
the ability to generate all the cells present in the embryo. However they 
cannot be defined totipotent, like the zygote, as they cannot give rise to 
extra-embryonic tissues. Adult stem cells have a more limited 
developmental potential, as they generate mature cells of the tissue in 
which they reside.1.1.	   Embryonic	   Stem	   (ES)	   Cells	   and	   induced	  Pluripotent	  Stem	  Cells	  (iPS) 
Embryonic stem cells (ESCs) are totipotent cells that can be derived from 
the inner cell mass (ICM) of a blastocyst during gastrulation. The ICM 
can be maintained in undifferentiated state, and upon differentiation it 
gives rise to embryoid bodies in which early embryonic cell lineages 
develop. ESCs represent a potential source of cells with virtually 
unlimited self-renewal and differentiation capacity. Since these cells are 
able to give rise to all of the somatic and germ line cells of the fully 
developed organism, they are “uncommitted” progenitors of the three 
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embryonic germ layers: ectoderm, endoderm and mesoderm. The ES cell 
is the prototype stem cell, as defined by its ability to indefinitely expand, 
self-renew, and give rise to more specialized progeny cells. Despite the 
totipotency of ES cells, they cannot be safely transplanted in 
immunocompromised hosts, because they give rise to teratomas, which 
are tumors containing multiple tissue types, including fully differentiated 
structures, such as teeth and hair. Therefore, they are not amenable for 
therapeutic approaches in vivo. 
Scientists discovered ways to derive embryonic stem cells from early 
mouse embryos more than 30 years ago (Evans et al., 1981). The detailed 
study of the biology of mouse stem cells led to the discovery, in 1998, of 
a method to derive stem cells from human embryos and grow the cells in 
vitro (hESCs) (Thomson et al., 1998). Six years ago, Takahashi and 
Yamanaka demonstrated that enforced expression of four key 
transcription factors, Oct4, Sox2, Klf4, and c-Myc, can reprogram mouse 
somatic cells such as fibroblasts to pluripotency, and achieve similar 
developmental potential as ESCs, without the requirement for an embryo 
(Takahashi and Yamanaka, 2006). They named these new cells ‘‘induced 
Pluripotent Stem Cells’’ or iPSCs. A year later, several groups, including 
Yamanaka’s, reported the successful generation of iPSCs from human 
somatic cells (Park et al., 2008, Takahashi et al., 2007). The expectation 
that iPSCs will offer the same therapeutic potential as hESCs and the 
robust and reproducible method of deriving iPSCs have generated 
hundreds of studies addressing in vitro disease modeling and cell therapy 
strategies in preclinical animal models. iPS cell lines have indeed now 
been generated from patients of several monoallelic and complex genetic 
disorders (reviewed in Wu et al., 2011). These developments have 
brought the field closer to the promises of in vitro disease modeling, 
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disease-specific pharmacological treatment testing, and in some instances 
individualized cell replacement therapy. Several examples of the 
differentiation of disease-specific iPSCs into the cell types that are 
implicated in the disorder’s pathogenesis have been reported, and 
therefore this technology is particularly attractive for the diseases for 
which animal models are either not available or do not accurately 
represent the human disease etiology. The technology for generation of 
induced pluripotent stem cells (iPSCs) has made significant contributions 
to various scientific fields, and the field of cancer biology is no exception. 
Although cancer is generally believed to develop through accumulation of 
multiple genetic mutations, there is increasing evidence that cancer cells 
also acquire epigenetic abnormalities during development, maintenance, 
and progression. Because the epigenetic status of somatic cells changes 
dynamically through reprogramming, iPSC technology can be utilized to 
actively and globally alter the epigenetic status of differentiated cells. 
Using this technology, a recent study has revealed that some types of 
cancer can develop mainly through disruption of the epigenetic status 
triggered by dedifferentiation (Yamada et al., 2014). 
The following question, which is still unanswered, is whether iPSCs can 
replace ESCs in clinical application and disease modeling. Several 
analyses indicate that iPSCs share many key properties with ESCs 
including morphology, pluripotency, self-renewal, and similar gene 
expression profiles. Comparisons of iPSCs and ESCs have indicated that 
major features of the ESC epigenome are reproduced in iPSCs, including 
genome-wide methylation patterns and the establishment of bivalent 
histone marks at specific loci (Guenther et al., 2010, Lister et al., 2011, 
Meissner, 2010). However, reprogramming assays in mouse cells have 
shown that differences in gene expression and differentiation potential are 
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observed specifically in early passage iPSCs and have led to the concept 
that an ‘‘epigenetic memory’’ of previous fate persists in these cells (Bar-
Nur et al., 2011, Kim et al., 2010, Polo et al., 2010, Ghosh et al., 2010, 
Marchetto et al., 2009). Epigenetic memory has been attributed to the 
incomplete removal of somatic cell- specific DNA methylation marks at 
regions in proximity to CpG islands known as ‘‘shores’’ (Kim et al., 
2010, Doi et al., 2009). The residual DNA methylation and gene 
expression pattern of the somatic cell of origin are lost upon serial 
passaging of the iPSCs, or after treatment with DNA methyltransferase 
activity inhibitors, suggesting that epigenetic memory contributes to 
identify cells that are incompletely reprogrammed (Kim et al., 2010, Polo 
et al., 2010). However, these findings suggest that disease modeling may 
be influenced by the specific cell type of origin, as iPSCs show distinct 
cellular and molecular characteristics based on which cell types of origin 
were utilized. This property may improve the ability to generate specific 
cell types to be used in cell replacement therapy, such as those cells that 
are difficult to generate by differentiation from ESCs, including insulin 
producing pancreatic β cells (Bar-Nur et al., 2011).  
In agreement with the epigenetic similarity of the two pluripotent cell 
types, comparative transcriptome analyses using microarray also indicate 
that hESCs and hiPSCs are highly alike on a global scale, with gene 
expression patterns clustering together, and separate from the somatic 
cells of origin (Plath et al., 2011). However, iPSCs may retain a unique 
gene expression signature, including that of microRNAs and long 
noncoding RNAs (Mikkelsen et al., 2008, Chin et al., 2009, Loewer et al., 
2010, Stadtfeld et al., 2010, Wilson et al., 2009).  
Permanent cell lines of pluripotent ESCs and iPSCs and our increasing 
ability to direct them into any cell type for therapeutic potential holds 
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enormous promise for future regenerative medicine. ESCs are considered 
to be the gold standard of pluripotency, while iPSCs offer the ability to 
develop cells from any adult individual, which holds the future possibility 
of curing degenerative diseases using cells or tissue grafts with perfect 
histocompatibility match. 
1.2. Adult Stem Cells 
Until recently, scientists primarily worked with two types of stem cells: 
embryonic stem cells and "adult" stem cells. 
Virtually in all adult tissues, discrete populations of stem cells maintain 
the replacement pool to replenish cells that are lost due to physiological 
turnover, injury, or disease. 
Tissue homeostasis requires the presence of multipotent adult stem cells 
that are capable of efficient self-renewal and differentiation; some of 
these have been shown to exist in a dormant, or quiescent, cell cycle state. 
Such quiescence has been proposed as a fundamental property of 
hematopoietic stem cells (HSCs) in the adult bone marrow, acting to 
protect HSCs from functional exhaustion and cellular insults to enable 
lifelong hematopoietic cell production. Recent studies have demonstrated 
that HSC quiescence is regulated by a complex network of cell-intrinsic 
and -extrinsic factors. 
Stem cells, which are undifferentiated pluripotent cells capable of 
extensive proliferation and self-renewal are able to respond to the body 
needs to expand accordingly to finely tuned mechanisms. 
Sometimes they divide after long periods of inactivity, as it is observed in 
pulmonary tissues, heart and pancreas, for instance. In other organs, such 
as the gut and the bone marrow, stem cells regularly divide to replace 
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cells.  
Stem cells share the ability to balance the cell fate decision of self-
renewal versus differentiation. The mechanisms that regulate cell fate 
choices have cell autonomous (stem cell intrinsic) and non-cell 
autonomous (microenvironmental) components. During divisional 
asymmetry, cell-fate determinants are asymmetrically localized to only 
one of the two daughter cells, which retain stem-cell fate, while the 
second daughter cell undergoes differentiation. During environmental 
asymmetry, after division, one of two identical daughter cells remains in 
what has been called the “self-renewing niche microenvironment”, while 
the other relocates outside the niche to a different differentiation-
promoting microenvironment. The niche also helps to integrate stem cells 
decisions related to maintaining quiescence versus proliferation, self-
renewal versus differentiation, migration versus retention, and cell death 
versus survival. 
1.3. Stem cell niche 
The self-renewal and differentiation activity of stem cells is controlled by 
their surrounding microenvironment, which is known as the stem cell 
niche. The stem cell niche is still poorly understood, as well as the precise 
location of the stem cells is not completely unravelled. The most 
characterized mammalian somatic stem cells are the murine HSCs, which 
reside in the bone marrow. The bone marrow HSC niche is a complex 
network. Many studies support the idea that there are at least two HSCs 
niches: the endosteal niche, in which the HSCs are closely associated with 
the osteoblasts, and the perivascular niche, where the HSCs are 
supposedly associated with the sinusoidal endothelium. It is also very 
  11 
likely that multiple niches exist, and that HSCs are not static, but instead 
dynamically change their niche location in response to injury or feedback 
signals (Trumpp et al., 2010). Taking advantage of mice that have 
received total body irradiation, it has been shown that the niche undergoes 
a dynamic remodeling process. In addition, it has been shown that some 
important cellular components of the niches are not restricted to the 
endosteum or the perivascular niche area, but are part of both 
environments, raising the possibility that both niches and the location of 
HSCs may not be as distinct as it is currently assumed. Mesenchymal 
Stem Cells (MSCs) are among the most important component of the 
HSCs’ niche. Méndez-Ferrer et al., (2010) identified a stromal Nestin-
expressing MSC population (Nestin+ MSC) that is closely associated with 
putative HSCs. Nestin+ MSCs are strictly perivascular and are typically 
found in more central areas of the marrow, but they are also present near 
the endosteum, although at lower frequency. Nestin+ MSCs are tightly 
associated with adrenergic nerve fibers of the sympathetic nervous system 
(SNS) that regulate HSC mobilization and are responsible for the 
circadian oscillations in circulating HSC numbers (Katayama et al., 2006; 
Méndez-Ferrer et al., 2008).  
These MSCs express higher levels of HSC maintenance factor transcripts, 
including stromal cell-derived factor 1 (SDF-1) also known as C-X-C 
motif chemokine 12 (CXCL12), stem cell factor (SCF), angiopoietin-1 
(Ang-1), interleukin-7 (IL-7), vascular cell adhesion molecule 1 
(VCAM1), and osteopontin (OPN), as compared to any other stromal cell 
type including the osteoblasts. Most interestingly, Nestin+ MSCs show 
several similarities to recently identified mesenchymal adipo-osteogenic 
progenitors (Sugiyama et al., 2006; Omatsu et al., 2010), discovered in a 
mouse strain in which GFP is driven by the endogenous CXCL12 locus 
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(Sugiyama et al., 2006; Omatsu et al., 2010). Because of their high 
CXCL12 expression and their long cellular processes, these cells were 
named CXCL12-abundant reticular (CAR) cells. The majority of putative 
HSCs are found in close proximity to CAR cells by 
immunohistochemistry and, like Nestin+ MSCs, CAR cells are 
predominantly found in the more central areas of the marrow; some being 
also located near endosteal vessels. Although CAR cells are more 
abundant than Nestin+ MSCs, they are tightly associated with the 
sinusoidal endothelium and have a similar morphology to vascular 
pericytes. These data are in agreement with studies in humans, suggesting 
that virtually all MSC activity is found within the larger pericyte 
population that associates closely with the vascular system throughout the 
body (Crisan et al., 2008).  
 
 
Figure 1. Location of HSC niches in trabecular bone cavities. HSCs are located at the 
endosteum, which is lined by osteoblasts (OBs) and is remodeled by osteoclasts. OBs promote 
HSC maintenance. Vascular sinusoids are found close to the endosteum, but more frequently 
at greater distances. HSCs are also situated nearby sinusoids toward the center of the 
marrow. Perivascular Nestin+ MSCs and the more abundant CAR cells promote HSC 
maintenance (Ehninger and Trumpp, 2011). 
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Similar to Nestin+ MSCs, CAR cells express HSC maintenance proteins 
such as CXCL12 and SCF. Induced depletion of CAR cells causes a 
partial loss of HSC activity associated with a decrease in HSC cycling, 
suggesting that CAR cells promote HSC cycling and self- renewal. CAR 
cells and Nestin+ MSCs represent two highly overlapping CXCL12-
expressing cell populations. In addition CAR cells are bipotent adipo-
osteogenic progenitors that show several similarities to Nestin+ MSCs. 
However Nestin+ MSCs containing Fibroblast Colony-Forming-Unit 
activity, are characterized by high self-renewal activity both in vitro and 
in vivo, and are capable of multilineage differentiation into bone, 
cartilage, and fat. It has been postulated that Nestin+ MSCs represent a 
more primitive population compared to CAR cells and may even be a 
CAR subpopulation (Ehninger and Trumpp, 2011). As it remains unclear 
whether Nestin+ MSCs are homogeneous and whether they all express 
high levels of CXCL12, it is possible that some Nestin+ MSCs may not be 
CAR cells.  
 
Figure 2. Model illustrating the quiescent endosteal and the active perivascular HSC niche 
during bone marrow homeostasis. (Ehninger and Trumpp, 2011). 
In an attempt to further identify and characterize cellular niche 
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components, a recent study suggests that Osterix+ - rather than mature 
Osteocalcin+ osteoblasts are required for the integrity of the niche 
(Raaijmakers et al., 2010). However MSCs express much higher levels of 
some HSC maintenance factors compared with osteoblasts (CXCL12, 
SCF, IL-7, VCAM1, and OPN) (Méndez-Ferrer et al., 2010).  
Another crucial cellular niche component is represented by the osteoblasts 
(OB). OBs produce factors that are known to be involved in HSC 
retention and maintenance, including CXCL12, OPN, and N-cadherin, in 
addition to factors that keep HSCs in a quiescent state, including 
Angiopoietin-1 (Ang-1), and membrane-bound SCF. OBs are also an 
exclusive source of thrombopoietin (TPO). TPO signaling via the c-MPL 
receptor mediates HSC quiescence, a typical feature of the most potent 
HSCs in steady-state bone marrow. c-MPL-/- mice are born with normal 
numbers of HSCs, but their frequency progressively declines with age, 
demonstrating a critical role for OB-derived TPO in adult HSC 
maintenance in vivo. 
Lastly, macrophages are a crucial niche component. Loss of monocytes 
and/or macrophages is associated with mobilization of HSCs out of the 
bone marrow into the peripheral blood and spleen. This is associated with 
a 40% reduction in CXCL12 protein in the bone marrow extracellular 
fluid. CXCL12-mediated activation of the CXCR4 receptor on HSCs is a 
critical niche retention signal. Macrophages in addition are positive 
regulators of the OB and Nestin+ MSCs that are required to maintain 
expression of various HSC retention factors, including CXCL12. 
Importantly macrophages mediate granulocytic-colony stimulating factor 
(G-CSF)-induced HSC mobilization, which is a common method to 
release HSCs in the peripheral blood where they can be recovered by 
apheresis and used in subsequent BM transplantation settings.  
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Figure 3. Model illustrating the quiescent endosteal niche and the active perivascular HSC 
niche after stimulation with G-CSF or depletion of monocytes/macrophages (Ehninger and 
Trumpp, 2011). 
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2. Mesenchymal Stem Cells (MSCs)  
Any adult tissue harbors tissue-specific stem cells defined as cells that 
self-renew and retain sufficient proliferative and differentiation potential 
to be able to repair and/or reconstitute the tissue itself. It is well known 
that adult bone has an impressive ability to repair; therefore, it is not 
surprising that the quest to identify and characterize the stem cells 
responsible for this process is an active field of investigation (Bianco et 
al., 2008, Caplan, 2007, Kolf et al., 2007, Prockop, 1997). In the early 
1970’s, the pioneering work of Friedenstein and colleagues demonstrated 
that the rodent bone marrow had fibroblastoid cells with in vitro 
clonogenic potential (Friedenstein et al., 1970). Friedenstein flushed out 
the whole bone marrow into plastic culture dishes, and, after discarding 
the non-adherent cells, isolated spindle-like cells adherent to the plastic, 
which were heterogeneous in appearance and capable of forming colonies 
(Colony-Forming Unit Fibroblasts, CFU-F). These cells could also make 
bone and reconstitute a hematopoietic microenvironment in subcutaneous 
transplants. Moreover, Friedenstein demonstrated that they could 
regenerate heterotopic bone tissue in serial transplants, thus providing 
evidence in support of their self-renewal potential. Over the years, 
numerous laboratories have confirmed and expanded these findings by 
showing that cells isolated according to Friedenstein’s protocol were also 
present in the human bone marrow. It was also demonstrated that these 
cells could be cultured for many passages and differentiated in vitro into a 
variety of cells of the mesenchymal lineages such as osteoblasts, 
chondrocytes, adipocytes and myoblasts (Bianco et al., 2008, Caplan, 
2007, Kolf et al., 2007, Pittenger et al., 1999, Prockop, 1997). 
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Friedenstein had thus isolated from the bone marrow the cells that Caplan 
and colleagues renamed as “Mesenchymal Stem Cells” or MSCs (Caplan, 
2007). In the adult bone marrow, MSCs are rare and their quantity 
changes during the lifetime, declining with age, as estimated by CFU-F 
assay. What controls the number of MSCs in the marrow and why these 
numbers appear to change with age is not yet known. Little is known 
about the phenotypic characteristics of in vivo MSCs, their developmental 
origin, their contribution to organogenesis and normal postnatal tissue 
homeostasis, as well as their precise anatomical localization. While 
multiple markers expressed in clonogenic stromal cells from human BM 
have been investigated as potential MSC markers, (Barry et al., 1999; 
Deschaseaux and Charbord, 2000; Gronthos et al., 1999; Shi and 
Gronthos, 2003; Simmons and Torok-Storb, 1991; Vogel et al., 2003; 
Zannettino et al., 2003), none of them is currently used to in situ identify 
MSCs. No evidence of asymmetric cell division, which is considered a 
property of self-renewing cells (Wu et al., 2008), has been provided yet 
for MSCs. While the multipotency of a fraction of human skeletal 
progenitors has been demonstrated (Kuznetsov et al., 1997), their ability 
to self-renew has not been formally determined for any subset of stromal 
cells. Furthermore, a faithful assay that would rigorously test for their 
ability to self-renew in vivo, and would thus prove their “true stemness” is 
still missing. Bianco strongly supports the need to develop in vivo assays 
based on the same rigorous principles used to design HSC bioassays. 
Stem cell function is indeed exhibited, as shown in the hematopoietic 
system, by the capacity of a single purified HSC to serially and long term 
reconstitute multilineage hematopoiesis in lethally irradiated recipient 
mice. Stringent and rigorous assays are based on three main points: (1) 
stemness is probed through in vivo transplantation experiments; (2) 
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multipotency can only be probed at the single-cell level; (3) self-renewal 
means reconstitution of a stem cell population identical in phenotype and 
function to the one originally explanted. Some of these inherent biological 
properties of the HSC system are not necessarily present in the MSC 
system or in other systems in which the investigation of the unique 
definition of stemness is still in progress. For example, single HSCs can 
be transplanted in vivo via the circulation, and distributed at high 
efficiency without ex vivo culture. On the other hand, sufficient numbers 
of MSCs, necessary to regenerate a skeletal defect, need to be locally 
transplanted, and even prospectively isolated; single skeletal progenitors 
need to be cultured to generate sufficient numbers of cells prior to 
transplantation.  
The capacity to self-renew relates to the rate of tissue turnover. While 
skin turns over every 30 days, the whole skeleton only turns over three to 
five times during adulthood. Consequently, self-renewal of stem cells 
capable of reforming skeletal tissues, in nature, would not be expected to 
involve the same number of cell divisions as for HSCs or epidermal stem 
cells.  
Therefore, since many questions still need to be properly addressed, it is 
also questionable if it is appropriate to refer to them as “mesenchymal 
stem cells” (Dominici et al., 2006; Horwitz et al., 2005). First, the original 
naming of this class of stem cells as mesenchymal was based on the 
hypothesis that multiple tissues beyond skeletal lineages could be 
generated by postnatal MSCs, including skeletal muscle, myocardium, 
smooth muscle, tendon, etc. (reviewed in Caplan, 2007). However, the 
non-skeletal potential of single MSCs has not been formally proven in 
vivo, and this issue remains controversial. Second, during prenatal 
organogenesis bone and skeletal muscle are generated by a system of 
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distinct progenitors, rather than from a common progenitor. Two 
opposing descriptions of MSCs exist at this time in cell biology (Bianco 
et al., 2013), making this field still rather controversial and in need of 
univocal nomenclature. “Mesenchymal” stem cells are the postnatal, self-
renewing, and multipotent stem cells that give rise to all skeletal tissues. 
This cell is part of a population of clonogenic progenitor cells, which 
coincide with a specific type of perivascular cell in the mammalian bone 
marrow. When explanted in culture, these progenitors generate a clonal 
progeny of transplantable stromal cells. Upon in vivo transplantation, 
these stromal populations generate ossicles, which include bone and bone 
marrow stroma of donor origin, as well as host-derived hematopoietic 
tissue and blood vessels within a marrow cavity. The single cell that 
initiates a clonal population in culture, which in turn can establish a 
complete organoid in vivo (including secondarily transplantable stromal 
cells) is a stem cell, as it is multipotent and self-renewing (Mendez-Ferrer 
et al., 2010, Sacchetti et al., 2007). MSCs are skeletal stem cells (Bianco 
et al., 2006) in that they are found in the skeleton; they are committed to 
skeletogenesis; they are capable of generating all different skeletal 
tissues; and they are able to recapitulate initial bone organogenesis in 
vivo. In skeletal physiology, this skeletal stem cell is essential to the 
growth and lifelong turnover of bone, as well as to its regenerative 
capacity. In hematopoietic physiology, it is a key player in maintaining 
hematopoietic stem cells in their niche, and in regulating multiple 
function of the hematopoietic microenvironment. In the alternative 
description, mesenchymal stem cells are not necessarily stem cells and not 
necessarily mesenchymal. They can also be multipotent stromal cells 
(Dominici et al., 2006), mesenchymal stromal cells (Horwitz et al., 2005), 
or even medicinal signaling cells (Caplan & Correa 2011). There are four 
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different terms for one invariant acronym (MSC), which contains four 
different meanings that do not originate from neither a physical in vivo 
entity nor from one defined concept. They describe, instead, a type of cell 
culturedefined by in vitro characteristics (Dominici et al., 2006), which 
are not even specific to stem cells, or reflective of a precise physiological 
function. These cultures can be established from virtually every 
connective tissue. This inconsistency introduced significant uncertainty, 
reflected in a debate over terminology, criteria, and standards that are in 
need of precise clarification.  
MSCs or MSC-like cells are mainly localized in the bone marrow; 
however they are also found in tissues such as fat, umbilical cord blood, 
amniotic fluid, placenta, dental pulp, tendons, synovial membrane and 
skeletal muscle. However the complete equivalence of such populations 
has not been formally demonstrated (Rogers and Casper, 2004, Bieback 
and Kluter, 2007, Xu et al., 2005, Shi and Gronthos, 2003, Tsai et al., 
2004, Bi et al., 2007, Igura et al., 2004, De Bari et al., 2001, Crisan et al., 
2008). Much effort has been invested both in in vitro expanding and 
phenotypically characterizing these cells, as well as in identifying factors 
involved in their regulation of proliferation and/or differentiation 
potential. The major aim being the possibility to transplant them back in 
vivo to repair specific tissues such as bone and cartilage (Tsutsumi, 2001, 
Kulterer et al., 2007, Pochampally et al., 2004, Hishikawa et al., 2004, 
Kratchmarova et al., 2005, Song et al., 2006).  
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Figure 4. MSCs and multipotent mesenchymal stromal cells. (Nombela-Arrieta et al., 2011) 
In our previous study (Picchi et al., 2012) we compared cellular and 
molecular characteristics of human adult MSCs derived from different 
body locations, such as bone marrow from iliac crest (Ic-MSCs), sternum 
(St-MSCs) and vertebrae (V-MSCs), as well as colon (Co-MSCs) and 
dental pulp (DPSCs). In particular, we investigated whether HOX genes 
and their TALE (three amino acid loop extension) co-factors provide 
specific molecular markers for stromal stem cell populations derived from 
different sources. Our results show that cell populations exhibiting similar 
immunophenotypes display different in vitro growth and differentiation 
properties, and are characterized by distinct HOX codes and TALE 
expression profiles. Furthermore, our data strongly suggest that molecular 
signatures differing only for the expression levels of specific HOX 
members may reflect differences in stem cell potency. Taken together, our 
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observations support the view that human MSCs derived from different 
body sites may not represent equivalent cell sources to regenerate specific 
tissues/organs. These observations may have important clinical 
implications, suggesting that successful tissue regeneration may depend 
on the source of MSCs employed for cell therapy or tissue engineering 
(Picchi et al., 2012). The notion that bone marrow includes skeletal 
progenitor (stem) cells, and the notion that BM stroma provides cues for 
homing, maintenance, proliferation, and maturation of hematopoietic 
progenitors both derive from classical transplantation experiments. The 
multipotency of at least a subset of CFU-Fs supports the view that a 
second type of skeletal stem cell (Bianco and Robey, 2010), stromal 
(Owen and Friedenstein, 1988), or ‘‘mesenchymal’’ (Caplan, 1991) co-
exists with the HSCs in the BM. HSCs would give rise to hematopoietic 
cell types and to osteoclasts, whereas MSCs would generate CFU-Fs and 
differentiate in vitro into a variety of mesenchymal lineages such as 
chondrocytes, adipocytes and osteoblasts. Since MSCs represent a distinct 
population from HSCs, they most probably have different cell surface 
antigens that would facilitate their purification from the hematopoietic 
stem cell component. Therefore, the identification of cell-specific cell 
surface markers for MSCs would be extremely useful. In the early 1980’s, 
a study from Simmons and colleagues led to the isolation of an antibody 
known as STRO1, which recognizes a cell surface antigen present in 
human bone marrow stromal cells. The STRO-1-positive population was 
highly enriched in clonogenic cells that were able to both generate CFU-
Fs and differentiate into multiple mesenchymal lineages in vitro 
(Simmons and Torok-Storb, 1991). The same group reported that the 
degree of homogeneity of the STRO-1-positive population could be 
further enhanced by positive selection for VCAM/CD106 (Gronthos et 
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al., 2003). In absence of specific and unique markers that would allow for 
a proper in vivo identification of MSCs, a histological localization of 
these cells is virtually impossible to achieve. Nevertheless, as reported by 
Caplan in 2007, every blood vessel in the body appears to have a 
mesenchymal cell on the tissue side of endothelial cells of large and small 
vessels. This endothelial layer is present in every tissue of the body, 
deriving from each of the germ layers. These vascular-associated 
mesenchymal cells are referred to as pericytes. When isolated and assayed 
in culture, these cells exhibit MSC-like characteristics. Conversely, 
marrow MSCs have markers characteristic of pericytes. Sacchetti and 
colleagues demonstrated that expression of high levels of CD146, a cell 
adhesion molecule of the immunoglobulin superfamily expressed in a 
restricted range of normal cells (Shih, 1999), identifies all ex vivo 
assayable CFU-Fs, and a specific subset of stromal cells in situ. 
Explantable CFU-Fs exhibit the same phenotype as Adventitial Reticular 
Cells (ARCs), which reside in bone marrow sinusoids next to the 
endothelial layer, strongly indicating that ARCs are in fact the cells 
explanted ex vivo as CFU-Fs. It has been shown that following 
transplantation of CD146+ stromal cells, a small subset retain CD146 
expression, dynamically associate with developing sinusoids, and 
eventually regenerate heterotopic human cells with the anatomy and 
phenotype of ARCs. Moreover, transplantation of cell populations 
derived from either a limited number of CD146+ CFU-Fs or single 
CD146+ CFU-Fs results in the re-establishment, in the heterotopic 
ossicles, of CD146+ CFU-Fs that can be secondarily passaged and directly 
assayed. These data directly identified a clonogenic, multipotent, self-
renewing stem cell in the bone marrow stroma, defining the MSC as a 
perivascular cell. Thus, the sinusoidal wall appears to act as a niche for 
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skeletal progenitors, while also acting as the niche for hematopoietic cells. 
These cells, which reside in the wall of the sinusoidal blood vessels of the 
bone marrow, are also positive for Ang-1, a critical regulator of vascular 
remodeling. The findings by Bianco and colleagues represent the first 
rigorous attempt to histologically localize and phenotypically define 
MSC-like cells, or at least a subpool of this population. Notably, a paper 
by Crisan and colleagues suggests that multipotent MSCs with 
perivascular localization exist in numerous human organs (Crisan et al., 
2008).  
Considerably less progress has been made in the characterization of the 
cell surface antigens that are expressed by murine MSCs in vivo. Van 
Vlasselaer and colleagues reported the purification of cells with 
osteogenic potential from murine bone marrow by two-color cell sorting 
using anti-Sca1 monoclonal antibody and wheat germ agglutinin (Van 
Vlasselaer et al., 1994). Simmons’ laboratory has identified a bone 
marrow pool of Sca1 (+) CD45 (-) CD31 (-) cells that appears to be 
enriched in MSCs/progenitors (Lundberg et al., 2007, Short et al., 2003). 
CD45, a pan-hematopoietic cell marker, and CD31 (PECAM), a classical 
marker for endothelial cells, were used in the study to negatively select 
for hematopoietic and endothelial cells, respectively. Interestingly, it was 
shown that a subset of CD45 (+) Lin (-) bone marrow cells was able to in 
vitro differentiate into a variety of cell types, including endothelial cells, 
osteoblasts, muscle cells, and neural cells (Rogers et al., 2007). This 
finding challenges the specificity of CD45 as a specific marker for 
hematopoietic cells. It raises the question whether the bone marrow 
contains pluripotent stem cells capable of generating tissues that 
embryologically derive from all the three embryonic germ layers. This is 
an appealing possibility for which, however, only a few pieces of 
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experimental evidence have been provided so far.  
A greater understanding of the biology of MSCs, particularly in their in 
vivo setting, will probably provide important insights into the cellular 
mechanisms of bone development, hematopoiesis, vasculogenesis and 
angiogenesis. As mentioned above, investigators have identified efficient 
protocol to expand MSCs isolated from bone marrow or adipose tissue 
aspirates, while still maintaining their multipotency (Caplan, 2007, 
Prockop, 2007). These cells have been transplanted at specific sites in 
experimental animal models by using appropriate scaffolds to form 
tissues such as bone and cartilage. However, no human MSC-based 
technology is currently available. Over the years, it has also become 
progressively clear that MSCs could be the basis for an extremely 
powerful “natural system of tissue repair” (Phinney and Prockop, 2007). 
MSCs can serve, upon exogenous administration, as effective therapeutic 
agents in a variety of experimental models of tissue injuries (Ortiz et al., 
2007, Kunter et al., 2006, Minguell and Erices, 2006, Lee et al., 2006, 
Phinney and Isakova, 2005). In the vast majority of these studies though, 
the therapeutic efficacy did not correlate with the efficiency of 
engraftment, which was generally low (Prockop, 2007). This finding 
suggests that the ability to repair was very likely due to secretion by 
MSCs of soluble factors that altered the tissue microenvironment, rather 
than cell fusion or transdifferentiation of MSCs into the appropriate cell 
phenotype, (Prockop, 2007). MSCs may thus provide what Caplan and 
colleagues define as “trophic activity” (Caplan, 2007). MSCs secrete 
bioactive factors which inhibit scarring and apoptosis and, conversely, 
stimulate angiogenesis and mitosis of tissue-intrinsic stem or progenitor 
cells (Caplan, 2007). 
Moreover, MSCs are characterized by immunoregulatory properties. In 
  26 
particular, MSCs have shown strong immunosuppressive effects. In 
particular, they inhibit T-cell recognition and expansion by inhibiting 
TNF-alfa and INF-gamma production and, thus increasing IL-10 levels 
(Beyth et al., 2005). These immunomodulatory effects support the use of 
allogeneic MSCs as therapeutic agents.  
If MSCs represent a natural system for tissue repair, then the next 
questions are 1) how MSCs are mobilized and 2) how they reach the site 
of injury. Natural chemo-attractive mechanisms can bring MSCs to the 
damaged sites and establish a regenerative microenvironment. 
Chemokines such as SDF1 and its receptor CXCR4 may have an essential 
role (Chamberlain et al., 2007) in directing MSCs to sites of injury. More 
recently, it has been reported that the cytokine receptor CCR2 and its 
intracellular adaptor molecule FROUNT are necessary for homing of 
bone marrow-derived mesenchymal stem cells to sites of injury (Belema-
Bedada et al., 2008). Little is known about how MSCs are mobilized from 
the bone marrow. It has been reported that MSCs can be observed in the 
circulating blood and that this circulating pool is dramatically increased 
by exposure to chronic hypoxia (Rochefort et al., 2006). The age of the 
individual, the extent of tissue damage and the local and total numbers of 
MSCs may play a role in their ability to regenerate damaged tissues. 
However upon direct delivery of MSCs to the injured sites, the 
regenerative process becomes more efficient. 
MSCs can also be grown in biocompatible scaffolds and implanted into 
different body sites, in order to well integrate them into the newly 
differentiated tissue (Caplan, 2007).  
Much still needs to be done to be able to employ MSCs as therapeutic 
agents in the future. A necessary precondition for an adequate 
characterization of the MSC population is the development of a 
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reproducible and faithful in vivo model that would test the ability of 
MSCs to self-renew, proliferate and differentiate in vivo, besides 
identifying their surface markers. The subcutaneous transplant model first 
introduced by Friedenstein and colleagues are undoubtedly very useful 
and informative, but they are not the equivalent of the primary and 
secondary bone marrow transplants that are classically used in the 
hematopoietic field to test stemness. Murine intratibial injection of MSCs 
and characterization of their contribution to bone homeostasis and 
fracture repair is becoming progressively more popular, (Wang et al., 
2003). An important goal, in addition to a proper in vivo characterization, 
would be the identification of pharmacological tools that could be used to 
expand in vivo and/or ex vivo the MSC pool. Some attempts in this 
direction have been already pursued: for example the proteosome 
inhibitor Velcade has been reported to be able to expand the MSC pool in 
a murine model in vivo (Mukherjee et al., 2008). A successful 
identification of useful pharmacological tools requires a detailed and 
systematic analysis of the complex network of signaling pathways and 
cells that regulate the ability of MSCs to self-renew, proliferate and 
eventually differentiate. The definition of a possible niche for MSCs and 
its regulation is another clear priority. The identification of this network is 
critically important, in order to reach a deeper understanding of the rules 
that govern the size of the in vivo MSC pool, which would eventually 
favor development of pharmacological interventions. It is likely that a 
global gene expression profiling approach could be extremely helpful to 
gain insights into the molecular mechanisms that regulate both the size 
and the differentiation potential of MSCs (Tsutsumi et al., 2001, Kulterer 
et al., 2007, Pochampally et al., 2004, Hishikawa et al., 2004, 
Kratchmarova et al., 2005, Song et al., 2006). 
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2.1. Molecular Differentiation Mechanisms 
Bone is a specialized connective tissue that provides structural support to 
skeletal muscle, physical protection to vital organs such as the brain and 
heart, a reserve for minerals such as calcium and phosphate, and a 
continuous source of hematopoietic stem cells for regeneration of cells of 
the blood and immune system. Given these vital roles, loss of normal 
bone structure and function is associated with various diseases, most 
notably osteoporosis. Throughout life bone is constantly remodeled 
through the processes of bone formation by osteoblasts, and bone 
resorption by osteoclasts. Developmentally, osteoclasts are derived from 
hematopoietic stem cell precursors of the monocyte/macrophage lineage 
located in the blood and the bone marrow (Teitelbaum et al., 2000), while 
osteoblasts originate from bone marrow MSCs (Owen et al., 1988). In 
normal, healthy bone, a balance of bone formation/resorption is achieved 
in large measure through the coordinated differentiation of these cell 
types from their stem cell precursors. Bone marrow MSCs can give rise 
not only to osteoblasts, but also to a range of other cell types including 
adipocytes, chondrocytes, and myoblasts (Chamberlain et al., 2007). 
Among these potential fates, differentiation to the osteoblast and 
adipocyte lineages has particular relevance to the maintenance of normal 
bone homeostasis. For example, considerable evidence exists to support 
that a shift in MSC differentiation to favor the adipocyte lineage over the 
osteoblast lineage can directly contribute to imbalances in bone 
formation/resorption, and lead to bone loss. This shift of MSC 
differentiation to the adipocyte lineage may contribute to the progressive 
increase in adipocyte formation and decrease in osteoblast number that 
coincides with age-related bone loss (Duque, 2008). In support of this 
  29 
reciprocal relationship, numerous in vitro experiments performed with 
bone marrow-derived MSCs have demonstrated that factors that induce 
adipogenesis inhibit osteoblast formation (Beresford et al., 1992, Dorheim 
et al., 1993) and, likewise, factors that promote osteoblastogenesis inhibit 
adipocyte formation (Gimble et al., 1995). Furthermore, the majority of 
conditions associated with bone loss, including aging, glucocorticoid 
treatment, increased cortisol production, and osteoporosis, also coincide 
with increased marrow adiposity (as reviewed in Chan and Duque, 2002, 
Kirkland et al., 2002). Adipocytes may further influence bone remodeling 
through the secretion of fatty acids and adipokines with paracrine actions 
that may influence the development and function of stem cells, 
precursors, as well as mature cell types such as osteoblasts and osteoclasts 
(Karsenty et al., 2006). Thus, given the close association between 
adipocyte and osteoblast formation, it is possible to prevent or treat bone 
loss by inhibiting bone marrow adipogenesis. In bone marrow, the 
developmental fate of MSCs is largely determined by the expression of 
specific groups of transcription factors that act as molecular switches to 
drive the differentiation of uncommitted precursors to a specific lineage. 
For example, expression of the transcription factors Runx2 and osterix 
(OSX) are the main determinants of MSC osteoblastogenesis (Ducy et al., 
1997, Nakashima et al., 2002). In contrast, the transcription factor PPARγ 
(Peroxisome Proliferator-Activated Receptor-γ) is the key factor that 
drives adipogenic differentiation of MSCs (Rosen et al., 2000).  
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Figure 5. Postulated inverse relationship between osteogenic and adipogenic programming 
(James, 2013). 
2.1.1. Adipogenesis 
Sinal’s group characterizes adipogenesis in two phases: the determination 
phase and the terminal differentiation phase (Muruganandan et al., 2009). 
In the determination phase, multipotent MSCs become committed to the 
adipocyte lineage, and lose their ability to differentiate into other 
mesenchymal lineages. During this phase, committed preadipocytes are 
morphologically indistinguishable from their precursors. Subsequently the 
terminal differentiation phase, preadipocytes are converted in mature 
adipocytes that acquire new specific functions, as they can synthesize and 
transport lipids, secrete adipocyte-specific proteins, and contain the 
machinery necessary for insulin sensitivity (Rosen et al., 2006). In 
addition to these two phases, several experimental cellular models of 
adipogenesis (e.g., the murine preadipocytes cell line 3T3-L1) require a 
period of mitotic clonal expansion, involving one or two rounds of cell 
division prior to committing to maturation. In human bone marrow 
MSCs, clonal expansion is not required for the adipogenic differentiation 
(Janderova et al., 2003). However, even though the mitotic clonal 
expansion has not been unequivocally established as a requisite for bone 
marrow adipogenesis, it is instead clear that some cell cycle proteins that 
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act to regulate mitosis also act in regulating some aspects of adipocyte 
differentiation (Tang et al., 2003). Functionally, adipogenesis reflects a 
fundamental shift in gene expression patterns within uncommitted MSCs 
that promotes and culminates in the phenotypic properties that define 
mature adipocytes (Rosen et al., 2000). Adipogenesis is driven by a 
complex and well-orchestrated signaling cascade involving regulated 
changes in the expression and/or activity of several key transcription 
factors, most notably PPARγ and several members of the 
CCAAT/Enhancer-Binding family of proteins (C/EBPs) (reviewed in 
Rosen et al., 2000). During in vitro adipogenesis, first, there is growth 
arrest of proliferating preadipocytes, usually achieved in cultured cell 
lines after contact inhibition. In culture cell models, initial growth arrest is 
induced by the addition of a pro-differentiative hormonal regimen and it 
is followed by one or two additional rounds of cell division known as 
clonal expansion. This process is coincident with the expression of the 
key transcription factors PPARγ and C/EBPα (Shao and Lazar 1997; 
Morrison and Farmer 1999). The induction of these two proteins is 
characterized by a second, permanent period of growth arrest followed by 
expression of the fully differentiated phenotype. Although growth arrest 
is virtually a sine qua non of the differentiation process, there is some 
debate about the requirement for clonal expansion in vivo. Several studies 
show that inhibition of cell division in cultured preadipocytic lines clearly 
blocks their subsequent differentiation. This process of terminal 
differentiation occurs over several days in cultured cell lines. A second, 
permanent state of growth arrest occurs following the accumulation of 
phenotypic markers of the mature adipocyte.  
Morphologically, the earliest events of adipogenesis include a rounding 
up of the fibroblast-like preadipocytes and the expression of specific 
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transcripts including lipoprotein lipase, and the transient induction of the 
transcriptional components C/EBPβ and C/EBPδ (MacDougald and Lane 
1995; Darlington et al., 1998). These earliest events are followed by the 
appearance of PPARγ and C/EBPα, which activate de novo or enhanced 
expression of most or all of the genes that characterize the adipocytic 
phenotype. These genes include glycerophosphate dehydrogenase, fatty 
acid synthase, acetyl CoA carboxylase, malic enzyme, Glut 4, insulin 
receptor, and aP2 (adipocyte-selective fatty acid binding protein) 
(Spiegelman et al., 1993). Throughout this process, lipid droplets begin to 
appear in the cytoplasm, and over time they become quite large and often 
fuse into one or a few major droplets. Studies in preadipocytic and 
fibroblastic cultured cell lines have provided insights into the 
transcriptional cascade that drives adipogenesis.  Three classes of 
transcription factor have been identified that directly influence fat cell 
development. These include PPARγ, C/EBPs, and the basic helix–loop–
helix family (ADD1/SREBP1c). PPARγ is a member of the nuclear 
hormone receptor superfamily, and, like many members of this class of 
transcription factor, PPARγ must heterodimerize with another nuclear 
hormone receptor (the retinoid X receptor, or RXR) to bind DNA and be 
transcriptionally active. The first “gain-of-function” experiments that 
linked PPARγ to fat cell development utilized retrovirally-expressed 
PPARγ in nonadipogenic, fibroblastic cells. Using the relatively 
nonspecific ligands available at the time, activation of PPARγ was shown 
to strongly induce adipogenesis (Tontonoz et al., 1994).  The effect of 
PPARγ activation regards all aspects of the mature fat cell phenotype, 
including morphological changes, lipid accumulation, and the acquisition 
of insulin sensitivity. PPARγ is a potent inducer of adipogenesis, as it can 
indeed promote the transdifferentiation of cultured myoblasts to 
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adipocytes, particularly when co-expressed with C/EBPα (Hu et al., 
1995). PPARγ knock-out mice do not survive past embryonic day 10–
10.5, due to a defect in their placental development (Barak et al., 1999; 
Kubota et al., 1999). This occurs prior to the formation of identifiable fat 
cells in mice. One approach to specifically pinpoint PPARγ contribution 
to adipogenesis was to create chimeric mice derived from both wild-type 
ES cells and cells with a homozygous deletion of PPARγ (Rosen et al., 
1999). This strategy allowed quantifying the contribution of PPARγ null 
cells to adult tissues in healthy animals. PPARγ was found to be required 
for in vivo adipogenesis. Interestingly, animals with only one PPARγ 
allele exhibited resistance to diet-induced obesity, although this results at 
least in part from elevated serum leptin levels, and decreased food intake 
(Kubota et al., 1999; Miles et al., 2000). PPARγ is also required for the 
differentiation of adipose cells from ES cells (Rosen et al., 1999) or from 
embryonic fibroblasts in vitro (Kubota et al., 1999).   
The C/EBP proteins belong to the basic-leucine zipper class of 
transcription factors. Six isoforms have been described, all of which act as 
homo- and/or heterodimers formed through a highly conserved bZIP 
domain (Lekstrom-Himes and Xanthopoulos 1998). Their tissue 
distribution is not restricted to fat cells, and a role for C/EBP proteins has 
been demonstrated in the terminal differentiation of granulocytes (Zhang 
et al., 1997) hepatocytes (Wang et al., 1995; Flodby et al., 1996), and 
pulmonary cells (Basseres and Levantini et al., 2006). C/EBPs also play 
an important role in resistance to infection (Yamanaka et al., 1997) and 
tissue response to injury (Flodby et al., 1996) in addition to 
transactivating a wide variety of target genes. C/EBPs can be regulated at 
many levels, including transcriptionally, as measured by mRNA levels in 
cells. There are many isoforms for these proteins. For example, the 42-kD 
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C/EBPα isoform is a stronger transcriptional activator than the 30-kD 
isoform, and the p42/p30 ratio increases during the course of adipogenesis 
(Lin et al., 1993). The amount of the 20-kD inhibitory isoform of C/EBPβ 
decreases during adipogenesis relative to the 32-kD active isoform 
(Bachmeier and Loffler 1997). Post-translational regulation of C/EBPs, 
particularly changes in phosphorylation, can modify the activity of C/EBP 
proteins as well. In cultured preadipocytic cell lines that have been 
induced to differentiate, C/EBPβ and δ mRNA and protein levels rise 
early and transiently (Cao et al., 1991; Yeh et al., 1995). C/EBPα, on the 
other hand, is induced later in the differentiation process, slightly 
preceding the induction of most of the end-product genes of fat cells. The 
proadipogenic role of C/EBPβ and δ was originally demonstrated in in 
vitro gain-of-function experiments. Ectopic expression of C/EBPβ is 
sufficient to induce differentiation of 3T3-L1 cells without the addition of 
hormonal inducers; similar experiments with C/EBPδ reveal that 
prodifferentiative agents are still required, but adipogenesis is accelerated 
(Yeh et al., 1995). Ectopic expression of C/EBPβ in NIH-3T3 fibroblasts 
is permissive for adipogenesis in the presence of hormonal inducers (Wu 
et al., 1995). Embryonic fibroblasts lacking either C/EBPβ or δ showed 
slight reductions in adipogenic potential, but cells lacking both C/EBPβ 
and δ were severely impeded from developing into adipocytes (Tanaka et 
al., 1997). Mice lacking either C/EBPβ or δ have normal white adipose 
tissue (WAT), although their brown adipose tissue (BAT) shows 
reductions in lipid accumulation. Mice that lack both C/EBPβ and δ, 
however, have a more dramatic phenotype. Approximately 85% of these 
animals die in the perinatal period of unknown causes; the remaining 15% 
that survive have sharply reduced BAT and smaller decreases in WAT 
(Tanaka et al., 1997). Interestingly, the reduction in BAT appears to be a 
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result of reduced lipid accumulation, whereas the reduction in WAT is 
reported to involve hypoplasia, despite the few adipocytes that develop 
show normal size, morphology, and gene expression profiles. The 
involvement of C/EBPα in adipogenesis is also strongly supported by in 
vitro data. Overexpression of C/EBPα in 3T3-L1 preadipocytes induces 
their differentiation into mature fat cells (Freytag et al., 1994; Lin and 
Lane 1992).Animals that carry a homozygous deletion of the C/EBPα 
gene have dramatically reduced fat accumulation in WAT and BAT pads 
(Wang et al., 1995). These experiments have led to a model for a 
transcriptional network in adipogenesis involving the sequential 
activation of C/EBPs and PPARγ In this model, one major function of 
C/EBPβ and δ is to induce the expression of PPARγ. This induction is 
likely to be a direct transcriptional effect through C/EBP binding sites in 
the PPARγ promoter (Zhu et al., 1995; Fajas et al., 1997). PPARγ, is then 
responsible for inducing C/EBPα. Evidence for this cascade comes first 
from the temporal sequence of PPARγ and C/EBPα expression during 
adipogenesis, as well as from gain-of-function experiments in which 
ectopic expression of PPARγ or the application of specific PPARγ ligands 
induces C/EBPα mRNA. Genetic proof of this relationship was obtained 
from experiments in which cells (embryonic fibroblasts or embryonic 
stem cells) that are homozygous null for PPARγ were exposed to pro-
differentiative signals. These cells do not become adipocytes and they 
express C/EBPα very poorly, despite normal levels C/EBPβ and δ 
(Kubota et al., 1999; Rosen et al., 1999). Interestingly, fibroblasts made 
from C/EBPα-/- embryos have reduced levels of PPARγ and do not form 
fat readily when exposed to hormonal inducing agents in culture (Wu et 
al., 1999). When C/EBPα is added back to these cells with a retroviral 
vector, the expression of PPARγ (and the ability to differentiate) is 
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restored. This reveals a positive feedback loop within the cascade, in 
which there is mutually reinforcing expression of PPARγ and C/EBPα; 
this feature ensures that, once initiated, the cascade will maintain the 
expression of these critical factors and, therefore, the terminally 
differentiated state. It is not certain whether the actions of C/EBPs and 
PPARγ is parallel and reinforcing pathways of adipogenesis, or whether 
there is really one factor that drives adipogenesis. It is already known that 
PPARγ can stimulate most, but not all, aspects of adipogenesis in 
C/EBPα-deficient cells (Wu et al., 1999), hinting to PPARγ as the master 
regulator of adipogenesis. Fat cells lacking C/EBPα accumulate lipid and 
express most adipogenic markers, but they have poor insulin sensitivity. 
This is a result of decreased levels of insulin receptor and one of its 
primary substrates (IRS-1), as well as an unclear defect in insulin 
signaling. C/EBPα could cause a lack of proper differentiation, as it is 
usually needed to completely-terminally differentiated cells. 
Coactivator proteins play a key role in gene expression activation, as they 
unfold the chromatin structures. Once the chromatin has been opened up, 
transcription factors can bind to DNA and subsequently activate gene 
expression. The interaction of multiple coactivators with transcription 
factors in different temporal and spatial contexts provides another 
possible level of regulation to gene expression. Nuclear hormone 
receptors such as PPARγ, for example, can interact with coactivators like 
the p160 family, CBP/p300, and others. These proteins bind to the 
carboxy-terminal transcriptional activation function-2 (AF-2) domain of 
nuclear hormone receptors in the presence of ligand binding. Two 
dominant classes of coactivator complex have been reported to be 
recruited to nuclear hormone receptors: the p160/CBP/p300 complex and 
the DRIP/TRAP complex.  The first type is represented by SRC-
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1/NCoA1, TIF2/GRIP1/NCoA2, and pCIP/ACTR/AIB1 (Leo and Chen 
2000). In addition to binding the AF-2 domain of PPARγ, these proteins 
also interact with CBP/p300 (Yao et al., 1996). CBP/p300 can also 
interact directly with PPARγ, thus providing potential stability to the 
complex through multiple contact points (Gelman et al., 1999). The p160 
proteins and CBP/p300 both possess intrinsic histone acetyltransferase 
(HAT) activity, which is necessary to open the chromatin structure to 
allow full activation of transcription. The second class of coactivators that 
interact with nuclear receptors in a ligand dependent manner is the 
DRIP/TRAP/ARC complex (Fondell et al., 1996; Naar et al., 1999; 
Rachez et al., 1999). Interestingly, DRIP205/TRAP220 shares identity 
with PBP (PPARγ binding protein). The PBP null mutation is embryonic 
lethal because of defects in placental development, a phenotype shared 
also by PPARγ null embryos (Zhu et al., 2000). However, since PPARγ 
transcriptional activity is only modestly affected in cells lacking PBP, the 
requirement for this factor in PPARγ-mediated adipogenesis remains to 
be determined. Two coactivators of PPARγ that are not ligand dependent, 
but which show considerable biological selectivity, are PPARγ 
coactivator-1 and -2 (PGC-1,-2). Although it does not appear that PGC-1 
has endogenous HAT activity, it does interact through its amino-terminus 
with p160/CBP/p300, proteins that do possess such activity (Puigserver et 
al., 1999). One of the most interesting aspects of PGC-1 is its tissue 
distribution, in that it is expressed in brown but not white fat. Little is 
known about coactivator complexes interacting with C/EBP family 
members. Two types of coactivators have been reported to interact with 
C/EBPβ. One is the chromatin remodeling SWI/SNF complex that is 
recruited in myeloid cells to activate certain target genes (Kowenz-Leutz 
and Leutz 1999). The second type is the CBP/p300 coactivator (Mink et 
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al., 1997). Because it is also a potent activator of PPARγ, it is possible 
that CBP/p300 is important in the synergistic effects seen between C/EBP 
proteins and PPARγ.  
Other important questions focus on the identification of transcription 
factors that regulate development of early mesenchymal precursors, 
before their determination to the adipogenic lineage. Extracellular factors 
and intracellular signal transduction pathways can influence both in vitro 
and in vivo the adipogenic potential. These include the hormones that 
induce adipogenesis, such as insulin-like growth factor-1 (IGF-1), insulin, 
growth hormone, glucocorticoids, and thyroid hormone, as well as 
intracellular pathways involving cAMP and p38 MAP kinase (Gregoire et 
al., 1998). There are also agents that inhibit fat cell formation, including 
cytokines such as IL-1 and TNF-α, cell surface proteins such as the 
preadipocyte-specific protein Pref-1, and intracellular pathways involving 
MAP kinases such as Erk1, Erk2, and JNK (Gregoire et al., 1998). The 
link between these factors and the transcriptional factors that regulate 
adipogenesis remains unclear, although some relationships have become 
clearer recently. For example, the well-documented inhibition of 
adipogenesis by MAP kinases can be at least partially explained by the 
phosphorylation of specific residues of PPARγ (Hu et al., 1995; Adams et 
al., 1997; Camp and Tafuri 1997; Font de Mora et al., 1997) and RXR 
(Solomon et al., 1999), which inhibits their activity. Although most 
studies have been devoted to the role of PPARγ and C/EBP proteins, it is 
known that a large number of other transcription factors and cofactors are 
regulated during adipogenesis. These factors may play a role in the 
expression of subsets of genes within the terminally differentiated 
adipocyte. Consistent with this idea, recent reports link other 
transcriptional regulators to the adipogenesis cascade, such as the 
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Kruppel-like zinc finger transcription factor family members KLF2 
(which represses adipogenesis) (Banerjee et al., 2003) and the 
proadipogenic KLF5 (Oishi et al., 2005) and KLF15 (Mori et al., 2005). 
Similarly, the zinc finger-containing factor KROX 20 (Chen et al., 2005) 
has been shown to participate early in the adipogenic cascade. A number 
of other transcription factors have also been shown to negatively regulate 
adipogenesis, for example, GATA-2 and -3 (Tong et al., 2000, Tong et 
al., 2005), the forkhead transcription factors FoxO1 (Nakae et al., 2003) 
and FoxA2 (Wolfrum et al., 2003), the HMG proteins TCF/Lef (Kennel et 
al., 2003), and SMAD-3 (Choy et al., 2003). These findings suggest that 
fat cell development is a more complex process than previously 
appreciated, requiring the integration of multiple transcriptional regulators 
to determine differentiation and function of the mature adipocyte. The Ebf 
family of helix-loop-helix transcription factors plays a significant role in 
B lymphocyte and neuronal development. The three primary members of 
this family, Ebf1, 2, and 3, are all expressed in adipocytes, and Ebf1 
promotes adipogenesis when overexpressed in NIH 3T3 fibroblasts. 
 Rosen and colleagues performed loss and gain-of-function approaches in 
multiple adipogenic and nonadipogenic cell types. Results indicate that 
there is a short but intense increase of Ebf1 expression after addition of 
the proadipogenic cocktail, followed by a return to a baseline that appears 
to be maintained for the life of the mature adipocyte. Ebf2 and Ebf3 do 
not display the same pattern of expression, and although they increase 
gradually later in development, they never reach peak levels equivalent to 
that of Ebf1. Moreover, retroviral delivery of shRNA to specifically 
“knock down” each Ebf isoform in turn has been performed. 
Differentiation did not proceed in the presence of reduced levels of either 
Ebf1 or Ebf2, strongly suggesting that these two factors have non-
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redundant activities. Specific Ebf3 “knockdown” did not result in changes 
in lipid accumulation or expression of marker genes like aP2. These 
experiments establish the importance of Ebf1 and Ebf2 and inform us that 
these proteins play a role in the process that cannot be compensated by 
other members of the family. Altogether, these data place Ebf1 within the 
known transcriptional cascade of adipogenesis and suggest critical roles 
for Ebf1 and Ebf2. Data suggest that Ebfs promote adipogenesis by 
inducing expression of C/EBPα and PPARγ, moreover enhancement of 
endogenous PPARγ and C/EBPα expression in adipocytes transfected 
with Ebf1 occurs. The evidence that PPAR is a direct target of Ebf1 
includes presence of Ebf motifs in the PPARγ promoter. Ebf1 directly 
binds and activates the C/EBPα promoter, thus exerting positive feedback 
on C/EBPδ expression. Ebf1 itself is induced by C/EBPβ and δ which 
binds and activates its promoter. These experiments place Ebf action 
between C/EBPβ/δ and C/EBPα/PPARγ, and a positive feedback loop 
involving C/EBPδ, Ebf1, and C/EBPα occurs during adipogenic 
differentiation (Jimenez et al., 2007). 
While there has been significant progress in determining the 
transcriptional cascade involved in terminal adipocyte differentiation, less 
is known about early events leading to lineage commitment and cell fate 
choice. It has been recently discovered that zinc finger protein 423 
(Zfp423) is an early actor in adipose determination. A close paralog of 
Zfp423, Zfp521, acts as a key regulator of adipose commitment and 
differentiation in vitro and in vivo. Zfp521 exerts its actions by binding 
Ebf1, a transcription factor required for the generation of adipocyte 
progenitors, and inhibiting the expression of Zfp423. Overexpression of 
Zfp521 in cells greatly inhibits adipogenic potential, whereas RNAi-
  41 
mediated knock-down or genetic ablation of Zfp521 enhances 
differentiation. In addition, Zfp521-/-embryos exhibit increased mass of 
interscapular brown adipose tissue and subcutaneous white adipocytes, a 
cell autonomous effect. Finally, Ebf1 participates in a negative feedback 
loop to repress Zfp521 as differentiation proceeds. Because Zfp521 is 
known to promote bone development, Rosen and colleagues suggest that 
it acts as a critical switch in the commitment decision between the 
adipogenic and osteogenic lineages (Kang et al., 2012). 
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2.1.2. Osteogenesis 
Bone formation is a strictly regulated process that takes place during 
embryonic development, growth, remodelling and fracture repair (Aubin 
2001). Bone formation is characterized by a sequence of events starting 
with the commitment of osteoprogenitor cells and their differentiation 
into pre-osteoblasts and then into mature osteoblasts whose function is 
synthesizing the bone matrix that becomes progressively mineralized. 
Several specific transcription factors are responsible for the commitment 
of pluripotent mesenchymal cells into the osteoblast cell lineage. One of 
the most important of these factors is Cbfa1 (core-binding factor α1), a 
transcription factor belonging to the runt-domain gene family, which 
plays a critical role in osteoblast differentiation, not being sufficient to 
support the achievement of the mature osteoblast phenotype (Banerjee et 
al., 1997; Ducy et al., 1997; Komori et al., 1997; Lee et al., 1999; Otto et 
al., 1997). Cbfa1 is highly expressed in osteoblast lineage cells and 
regulates the expression of various osteoblast-specific genes (Banerjee et 
al., 1997; Ducy et al., 1997; Ji et al., 1998; Harada et al., 1999; Tsuji et 
al., 1998); Cbfa1-deficient mice are completely defective in their bone 
formation ability (Hoshi et al., 1999), because of the maturational arrest 
of their osteoblasts. Over-expression of Cbfa1 induces non-osteogenic 
cells to express osteoblast-related genes (Yamaguchi et al., 2000). 
Another runt-related gene that plays an important role in the commitment 
of multipotent mesenchymal cells to the osteoblastic lineage, and required 
for osteoblast differentiation at an early stage is Runx-2, considered the 
master gene of osteogenesis. Runx-2 is involved in the production of bone 
matrix proteins (Komori et al., 1997; Otto et al., 1997), as it is able to up-
regulate the expression of many bone matrix protein genes, such as type I 
collagen, osteopontin, bone sialoprotein and osteocalcin (Ducy et al., 
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1997; Miyoshi et al., 1991; Ogawa et al., 1993) leading to an increase of 
immature osteoblasts from pluripotent stem cells; the immature 
osteoblasts form mature bone (Komori 2010). Runx-2 expression is 
down-regulated in the late stage of osteoblast maturation, when 
phenotypically mature osteoblasts form mature bone (Komori 2010). 
Runx-2-deficient mice are completely lacking in bone formation, because 
of an absence of osteoblasts (Komori et al., 1997; Otto et al., 1997). 
Osterix is also an essential transcription factor for osteoblast 
differentiation at an early stage (Ogawa et al., 1993), whereas it inhibits 
osteoblast differentiation at later stages (Komori 2003)  steoblast 
commitment, differentiation and growth are controlled by several local 
and systemic factors that can also act in a paracrine and/or autocrine way 
and that can regulate the activity of specific transcription factor (Aubin 
and Liu 1996). They include bone morphogenetic proteins (BMPs; 
Centrella et al., 1994), hedgehog proteins, cell growth factors (Canalis et 
al., 1993) such as fibroblast growth factor (FGF) and insulin-like growth 
factor (IGF), hormones (Cheng et al., 1994), cytokine modulators 
(Goldring and Goldring 1990), canonical Wingless (Wnt)/β-catenin 
(Ambrosetti et al., 2008; Hu et al., 2005; Mukherjee and Rotwein 2009) 
and mechanical physical forces (Baumbach et al., 1984; Buckley et al., 
1990). The progressive development of the osteoblast phenotype from a 
proliferating immature cell to a mature osteoblastic cell synthesizing 
specific bone proteins is characterized by a definite sequential expression 
of tissue-specific genes that identifies three distinct periods of osteoblast 
phenotype development: proliferation, maturation and extracellular matrix 
synthesis, and matrix mineralization. During the active proliferation 
phase, osteoblast-committed progenitor cells (pre-osteoblasts) express 
genes that support proliferation, and several genes encoding extracellular 
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matrix proteins, such as type I collagen and fibronectin. The precursors 
that undergo proliferation and differentiate into pre-osteoblasts unable to 
deposit bone matrix but are still capable of proliferating. In this phase, 
BMP-2 and BMP-5 play a significant role in increasing alkaline 
phosphatase activity (ALP), osteocalcin synthesis (Yamaguchi et al., 
1991) and parathyroid hormone (PTH9) responsiveness (Kodama et al., 
1982; Takuwa et al., 1991). Immediately after growth arrest, a 
developmental sequence involving the selective expression of specific 
genes that characterize the differentiated osteoblast phenotype (alkaline 
phosphatase, osteocalcin) occurs (Collart et al., 1991; Stein et al., 1992). 
The accumulation of matrix proteins contributes, in part, to the cessation 
of cell proliferation. The active bone-matrix-secreting osteoblasts are 
cuboidal cells, with a large Golgi apparatus and an abundant rough 
endoplasmic reticulum, and are provided with regions of plasma 
membrane specialized in the trafficking and secretion of vesicles that 
facilitate the deposition of bone matrix (Anderson 2003). During the post- 
proliferative phase, which is characterized by the high synthesis of 
alkaline phosphatase, the extracellular matrix progresses into the 
mineralization phase in which osteoblasts synthesize several proteins that 
are associated with the mineralized matrix in vivo (Franzen and Heinegard 
1985; Hauschka et al., 1989; Whitson et al., 1984), including sialoprotein 
(Nagata et al., 1991), osteopontin and osteocalcin (Gerstenfeld et al., 
1987; Owen et al., 1990). Osteopontin is expressed during the stage of 
active proliferation (25% of maximal level; Lian and Stein 1995), 
decreases immediately after the post-proliferative stage and increases 
again at the onset of mineralization, achieving the greatest level of 
expression during mineralization. Osteopontin might be involved in the 
control of the relationship between the cells and extracellular matrix, as 
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its amino acid sequence containing arg-gly-asp can mediate cell 
attachment (Oldberg et al., 1986). Osteocalcin is expressed by osteoblasts 
only in the post-proliferative phase. Osteocalcin is maximally expressed 
during mineralization in vivo (Hauschka et al., 1989) and in vitro (Owen 
et al., 1990). Several studies suggest that osteocalcin is involved in the 
regulation of mineral deposition and that it acts as a bone matrix signal 
that promotes osteoblast differentiation and activation (Chenu et al., 1994; 
DeFranco et al., 1991; Lian et al., 1984; Liggett et al., 1994), confirming 
that osteocalcin is a marker of mature osteoblasts (Lian et al., 1989, Lian 
et al., 1991). Osteocalcin synthesis is regulated by various hormones, and 
growth factors (e.g. TGF-β). The progression of matrix mineralization 
processes might be responsible for the down-regulation of genes 
expressed by mature osteoblasts. At the end of the synthesis and 
mineralization of the extracellular matrix, cellular levels of ALP mRNAs 
decline (Lian and Stein 1995) and 50–70% of the mature osteoblasts 
undergo apoptosis, whereas the surviving cells differentiate into lining 
cells or osteocytes; alternatively they transdifferentiate into cells that 
deposit chondroid bone (Franz-Odendaal et al., 2006). Lining cells remain 
on the bone surface, regulate the influx and efflux of mineral ions and 
retain the ability to re-differentiate into secreting osteoblasts, upon 
exposure to various stimuli (hormones, mechanical forces; Clarke 2008). 
Osteocytes are metabolically quiescent osteoblasts embedded in the bone 
matrix; they communicate with other bone cells through cell processes 
and function as strain and stress sensors (Lozupone et al., 1996). Bone is 
constantly undergoing remodelling, a complex process in which 
osteoblasts play an essential role. Bone remodelling is strictly regulated 
by several local and systemic stimuli, including bone micro-damage, the 
reduction or increase of mechanical loading, blood calcium levels, 
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hormones, cytokines and growth factors. The process of bone remodelling 
occurs in small groups of cells called basic multicellular units (BMUs), 
characterized by the coordinated action of osteoclasts and osteoblasts. The 
life-span of a single BMU is about 6-9 months during which several 
generations of osteoclasts (average life of about 2 weeks) and osteoblasts 
(average life of about 3 months) are formed. A bone remodelling cycle 
consists of four distinct and sequential phases: activation, resorption, 
reversal and formation.  
During the activation phase, osteoclastic precursors are recruited from 
circulating and bone-marrow mononuclear monocyte-macrophages 
(Roodman 1999), which differentiate into multinucleated cells, and 
actively resorbing osteoclasts that begin the resorption process. Osteoclast 
action is strictly related to their interaction with bone matrix proteins, 
including osteopontin and bone sialoprotein (Ross et al., 1993), which 
have been secreted by osteoblasts during the previous cycle of bone 
formation. When resorption has been completed, the reversal phase starts: 
the osteoclasts die through apoptosis and osteoblast precursors locally 
proliferate, differentiate into mature osteoblasts and migrate into the 
resorption site made by osteoclasts. In the following formative phase, 
osteoblasts synthesize new unmineralized bone matrix that fills the 
resorption site and becomes mineralized in the resting phase.  
2.2. Signaling pathways governing MSC osteogenic and 
adipogenic differentiation 
The balance between ostegenesis and adipogenesis is regulated by many 
signaling pathways that converge on the regulation of two main 
transcription factors: PPARγ and Runx2, generally regarded as the master 
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regulators of adipogenesis and osteogenesis, respectively. Signaling 
pathways are generally pro-osteogenic/anti-adipogenic stimuli. These 
include β-catenin dependent Wnt signaling, Hedgehog signaling (HH), 
and NELL-1 signaling, as well as bone morphogenic protein) signaling 
and insulin growth factor signaling, which display both pro-osteogenic 
and proadipogenic effects. In summary, understanding the factors that 
govern osteogenic versus adipogenic MSC differentiation has significant 
implications in diverse areas of human health, from obesity to 
osteoporosis to regenerative medicine.  
2.2.1. Wnt signaling 
Wnt signaling has been identified to play an essential role in cell fate 
determination, proliferation, and differentiation (Kim et al., 2013, Niehrs, 
2012). 
 Dysregulation/hyperactivation of Wnt signaling is associated with 
numerous diseases such as neurodegeneration (Berwick et al., 2012), 
gastrointestinal cancers (White et al., 2012), and osteoporosis (Kim et al., 
2013). Wnt signaling has demonstrated both proosteogenic and 
antiadipogenic activities, through both canonical (β-catenin dependent) 
and non-canonical (β-catenin independent) pathways. The β-catenin 
dependent pathway starts with the binding of extracellular Wnt ligands to 
the seven-pass transmembrane frizzled receptors (Frz) expressed at the 
cell surface (Xavier et al., 2014). This induces complex formation with 
transmembrane low-density lipoprotein receptor (LRP5/6) coreceptor, as 
well as intracellular proteins of the disheveled (DSH) family (Pandur et 
al., 2002). The resulting activation of DSH then functions to inhibit a 
second, intracellular complex comprised of axin, glycogen synthase 
kinase 3 (GSK3), and adenomatosis polyposis coli (APC) protein. GSK3 
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normally phosphorylates β-catenin, promoting its degradation. Wnt 
stimulation inhibits the Axin/GSK3/APC complex, and β-catenin 
accumulates rather than being degraded, and levels of nuclear β-catenin 
increase. Once inside the nucleus, β-catenin heterodimerizes with 
lymphoid enhancer-binding factor/T cell factor (Pandur et al., 2002). β-
catenin dependent Wnt signaling activates gene transcriptional activity, 
and determines MSC lineage commitment (Etheridge et al., 2004). While 
the noncanonical Wnt pathway is similar in that it involves extracellular 
Wnt binding to frizzled receptors (Frz) and DSH, it otherwise diverges to 
mediate its effects through a β-catenin independent manner (Wang et al., 
2004, Davis et al., 2008). 
Canonical Wnt signaling has well-established effects on bone mass in 
both animal models and human patients. LRP5 mutational studies first 
identified a critical role for Wnt signaling in bone maintenance (Case et 
al., 2010). LRP5 loss-of-function mutations cause pseudo-glioma 
syndrome, characterized by a low bone mass phenotype. Conversely, 
LRP5 gain-of- function mutations result in a high bone mass phenotype 
(Little et al., 2002, Gong et al., 2001, Boyden et al., 2002). A direct role 
for β-catenin in regulating osteoblast and osteoclast activity has been 
repeatedly observed (Chen et al., 2013). For example, in mesenchymal 
osteoblastic precursors, β-catenin deficiency leads to arrest of osteoblast 
development at an early stage and consequent embryonic skeletal defects 
(Chen et al., 2013, Hu et al., 2005, Day et al., 2005, Hill et al., 2005). 
Moreover, in committed osteoblasts, β-catenin deficiency results in 
impaired maturation and mineralization (Holmen et al., 2005, Glass et al., 
2005). Wnt/β-catenin signaling activity in both mature and osteoblastic 
precursors leads to reductions in osteoclast activity and bone resorption, 
as well (Takahashi et al., 2011, Nie et al., 2012). Accordingly, current 
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clinical applications for osteoporosis target Wnt inhibitors in order to 
stimulate formation of new bone and inhibit bone resorption. Currently 
targeted Wnt signaling antagonists include Sclerostin (SOST) and 
Dickkopf-1 (DKK1) (Gatti et al., 2012). As expected, inhibition of these 
antagonists, via anti-SOST and anti-DKK1, has been shown to stimulate 
bone formation and increase bone mineral density, respectively. Phase II 
clinical trials (for anti-SOST) and preclinical trials (for anti-DKK1) are 
currently underway (Lim et al., 2012, Papapoulos et al., 2011).  
Various members of the Wnt signaling family have been identified to 
inhibit the early stages of adipogenesis (Laudes et al., 2011). For 
example, WNT10B has been shown to maintain 3T3-L1 preadipocytes in 
an undifferentiated state by inhibiting PPARγ and C/EBP𝛼 (Ross et al., 
2000, Liu et al., 2004, Laudes et al., 2011). Similarly, activation of β-
catenin through ectopic expression of Wnt1 also leads to direct 
suppression of PPARγ and prevention of 3T3-L1 cell adipogenic 
differentiation (Ross et al., 2000, Liu et al., 2004). Interestingly, this 
negative inhibition is reciprocal, in fact up-regulation of PPARγ functions 
inhibit β-catenin signaling (Ross et al., 2000, Liu et al., 2004, Moldes et 
al., 2003). Conversely, inhibition of Wnt/β signaling through treatment 
with DKK family proteins positively regulates adipogenesis (Laudes et 
al., 2011, Ross et al., 2000, Bennett et al., 2002). Additional studies 
suggest that the canonical ligand Wnt3a has antiadipogenic effects, by 
inhibiting activation of both PPARγ and C/EBP𝛼 (Kawai et al., 2007). 
However, while PPARγ up-regulation may negatively regulate Wnt/β-
catenin signaling, overexpression of PPARγ and/or C/EBP𝛼 is not 
sufficient in rescuing Wnt/β-catenin-mediated inhibition of adipogenesis 
(Muruganandan et al., 2009, Kawai et al., 2007). In general, Wnt/β-
catenin signaling pathway activation follows the inverse pattern between 
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the induction of MSC osteogenic and adipogenic differentiation. The 
activation of Wnt/β-catenin, via lithium chloride, for instance, inhibits 
GSK3b, which generally results in both promoting osteogenesis and 
suppressing adipogenesis (Li et al., 2008, Galli et al., 2013). Similarly, 
Wnt10b stimulates in vivo osteogenesis by increasing bone mass and by 
blocking adipogenesis in preadipocytes in vitro via stabilization of free 
cystolic β-catenin (Ross et al., 2000, Bennett et al., 2002, Bennett et al., 
2007). Other canonical Wnt ligands, such as Wnt6 and Wnt10a, exhibit 
similar effects in stimulating osteogenesis and concurrently inhibiting 
adipogenesis (Cawthorn et al., 2012). Not surprisingly, disruption of 
Wnt/β-catenin impairs in vitro osteogenesis (Holmen et al., 2005, Glass et 
al., 2005) while increasing adipogenesis both in vitro and in vivo (Ross et 
al., 2000, Bennett et al., 2002, Castro et al., 2004). Moreover, inhibitors 
of the Wnt/β-catenin pathway demonstrate consistency with this inverse 
relationship between osteo- and adipogenic differentiation. DKK1, for 
instance, which is secreted by preadipocyte cells, inhibits osteogenesis 
while promoting adipogenesis in vitro (Gustafson et al., 2010). The 
inverse relationship carries over to the non-canonical branch of Wnt 
signaling as well. Wnt5a, for instance, has been shown to suppress pro-
adipogenic PPARγ transactivation when co-induced with pro-osteogenic 
Runx2 in MSC (Muruganandan et al., 2009, Takada et al., 2007). Thus, as 
observed with multiple ligands and inhibitors, Wnt signaling generally 
exhibit pro-osteogenic and anti-adipogenic effects in both canonical and 
non-canonical signal transduction pathways.  
 
2.2.2. Hedgehog signaling 
Sonic Hedgehog (SHH) and Indian Hedgehog (IHH) are critical during 
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embryological development. In particular, SHH plays a key role during 
skeletogenesis, involved in patterning of the axial, appendicular, and 
facial skeleton (Riddle et al., 1993, Ruat et al., 2012). Closely related to 
SHH through gene duplication, IHH regulates both chondrogenesis and 
endochondral bone formation (Bitgood et al., 1995). In fact, disruption of 
HH signaling results in severe skeletal abnormalities, the most common 
of which being holoprosencephaly (Nanni et al., 1999). By regulating 
stem cells fate, SHH is a critical modulator of cell differentiation, and it 
demonstrates pro-osteogenic and anti-adipogenic properties in multiple 
MSC types (James et al., 2010). All three HH morphogens (Sonic, Indian 
and Desert) follow the same, highly conserved HH signaling pathway. 
First, the insoluble HH polypeptide precursor undergoes conversion into a 
soluble, multimeric form capable of diffusing across the cell membrane. 
This is then auto-catalytically processed from a 45 kD to a 19 kD protein, 
with modifications for a cholesterol moiety at the C-terminal and 
palmitate at the N-terminal (Simpson et al., 2009). Subsequently, the 
modified HH morphogen is secreted from the cell via Dispatched, a large 
transmembrane protein. Then, it binds to the receptor Patched (PTCH), a 
12-pass transmembrane protein, on the receiving cell. This binding to 
PTCH relinquishes Smoothened (SMO), a 7-pass transmembrane protein, 
from PTCH suppression, thereby allowing activation of the glioblastoma 
gene products (Gli) family of transcription factors (Gli1-3). Since Gli1 is 
a target gene of the HH pathway, it is used as a reliable marker for HH 
signaling activity (Tzameli et al., 2004). The anti-adipogenic potential of 
HH signaling in MSC has been observed across a variety of adipocyte and 
multipotent cell lineages. Generally, adipogenesis in MSC, as it relates to 
HH signaling, occurs as a result of decreased Gli1, Gli2, Gli3, and PTCH 
expression (Fontaine et al., 2008). Conversely, when the HH pathway is 
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upregulated via the SMO (Smoothened)-activated inducer of HH 
signaling (Sinha et al., 2006), there is a significant decrease in adipocyte-
specific markers: adipocyte fatty acid binding protein, adipsin, CD36, 
adiponectin, and leptin. Through the inhibition of adipogenic genes, HH 
signaling ultimately decreases sensitivity to insulin, which in turn reduces 
the expression of adipogenic transcription factors, such as C/EBP𝛼 and 
PPARγ (Fontaine et al., 2008). Specifically, HH signaling blocks 
differentiation of white adipocytes. In addition to its anti-adipogenic 
properties, HH signaling is well known to stimulate MSC osteogenic 
differentiation. While the exact mechanism and stage at which HH acts 
during osteoblastogenesis are not completely understood, both in vivo and 
in vitro data suggest that bone formation occurs through a positive 
feedback loop. That is, HH-induced osteoblastogenesis requires BMP 
signaling, and together they bring to a synergistic expression of ALP 
activity (Yuasa et al., 2002). This positive feedback loop is further 
mediated by Gli2 transcription, which serves to upregulate BMP-2 
expression, which in turn activates Gli2 transcription itself (Zhao et al., 
2006). SHH- induced differentiation is only observed in the immature 
mesenchymal cell lines 3H10T1/2 and not in the pre-osteoblastic MC3T3-
E1, or the osteoblastic cell lines OS 17/2.8 and ROB-C26 (Yuasa et al., 
2002, Spinella-Jaegle et al., 2001). These data suggest that SHH activity 
may be crucial in stimulating osteoblastogenesis in early stages of cell 
differentiation. In summary, HH signaling promotes MSC osteogenic 
differentiation over adipogenic differentiation, primarily via Gli 
transcriptional factor/s activity.  
2.2.3. NELL-1 signaling 
NELL-1 overexpression selectively increases differentiation and 
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mineralization in osteoblasts and is highly specific to the osteochondral 
lineage (Zhang et al., 2010). Transgenic mice overexpressing NELL-1 
show premature cranial suture fusion and bone overgrowth,. This finding 
suggests a relative osteo-specific effect of NELL-1 signaling. Conversely, 
down-regulation of NELL-1 resulted in inhibited osteoblastogenesis in 
vitro in primary cultures of fetal rat calvarial cells and MC3T3 cell line 
cultures (Zhang et al., 2002). Moreover, complete loss of NELL-1 in mice 
results in significant reduction in the mineralization of calvarial bones and 
attenuated osteoblastogenesis (Zhang et al., 2012). Thus, NELL-1 has 
been shown to have a critical role in craniofacial osteogenic 
differentiation and bone formation (Zhang et al., 2002). NELL-1 has 
comparable bone regeneration capacity to BMP-2, in both calvarial defect 
and spinal fusion models. It is directly regulated by the transcription 
factor Runx2 (Zhang et al., 2011, Zhang et al., 2010, Lu et al, 2007). 
NELL-1 is preferentially expressed in osteoblasts in levels similar to 
Runx2, and it is most highly expressed during skeletogenesis (Zhang et 
al., 2011, Zhang et al., 2010). In Runx2 deficient mice, overexpression of 
NELL-1 is not sufficient to rescue mineralization, whereas absence of 
NELL-1 significantly sRunx2 activity in vitro (Zhang et al., 2011). 
Integrin-β1 was recently identified as the first cell surface receptor for 
NELL-1 (Shen et al., 2012). Cell surface binding in a preosteoblast cell 
line required Integrinβ1 expression (Shen et al., 2012). Moreover, siRNA 
for Integrinβ1 blocked at least some of the cellular effects of NELL-1, 
including induction of preosteoblast attachment (Shen et al., 2012). 
NELL-1 is known to promote osteogenesis accompanied by activation of 
MAPK, canonical Wnt and HH signaling (James et al., 2011, James et al., 
2012, Chen et al., 2012). NELL-1 activates both ERK1/2 and JNK1 
MAPK pathways in Saos-2 osteosarcoma cell type (Chen et al., 2012). 
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This activation of MAPK signaling is associated with Runx2 protein 
phosphorylation (activation) (Chen et al., 2012). In addition, NELL-1 
induced MAPK activity is accompanied by activation of phosphate 
transporters Pit1 and Pit2 to increase preosteoblast mineralization (Cowan 
et al., 2012). NELL-1 induction of Wnt signaling has been observed in 
both osteoblastic and osteoclastic cell types and is associated with its pro-
osteogenic and antiosteoclastic effects (James et al., 2011). Recent data 
have shown that NELL-1 also has anti-adipogenic effects, found both in 
the preadipocyte cell line 3T3-L1 cells, as well as in the primary adipose-
derived MSCs (ASC) (James et al., 2011). This was observed both in 
adipocyte specific gene expression and intracellular lipid accumulation. 
Recent in vivo studies have confirmed the anti-adipogenic effects of 
NELL-1, in which direct intramedullary injection of NELL-1 reduced 
intramarrow adipocytes in a senile rat model Kwak et al., 2013). These 
antiadipogenic effects of NELL-1 in preadipocytes are associated with 
activation of HH signaling. These effects may be through 
activation/intersection with MAPK, Wnt, and HH signaling.  
2.2.4. Bone morphogenetic proteins (BMPs) 
Bone morphogenetic proteins (BMPs), members of the transforming 
growth factor-β (TGF-β) superfamily, are extracellular cytokines 
originally isolated from bone extract and found to induce ectopic 
chondrogenesis and osteogenesis (Wozney et al., 1988). BMPs are 
responsible for numerous cell regulatory processes, including the 
differentiation and patterning of bone and cartilage (Chen et al., 2004). 
Over 20 different BMPs have been identified, of which BMP-2, -4, -7, -9, 
and -13 are most commonly studied in the context of MSC differentiation 
(Kang et al., 2009, Bragdon et al., 2011). Both recombinant BMP-2 and -
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7 are approved by the FDA for bone regeneration in spinal fusion surgery, 
and they are commonly used for other orthopaedic applications (Freire et 
al., 2011, Firedlaender et al., 2001). BMPs produce their effects through 
interaction with two serine-threonine kinase cell surface BMP receptors 
(BMPRs). Type II BMPRs initiate signaling upon binding to a BMP 
ligand, following which recruitment, phosphorylation, and activation of 
type I BMPRs occurs (Chen et al., 2004, Miyazono et al., 2005, Nohe et 
al., 2004). While there are several different types of BMPRs, only a few 
are involved in MSC differentiation, including BMPR-IA and BMPR-IB 
(Chen et al., 1998). Several downstream BMP signaling elements exist, 
including Smad1/5/8, MAP Kinase, and c-Jun N-terminal kinase (JNK) 
signaling pathways, which are phosphorylated and thereby activated 
(Chen et al., 1998, Tzameli et al., 2004, Nishimura et al., 2012). 
Transcriptional regulation of adipogenic and osteogenic during MSC 
commitment is regulated by Smad1/5/8 signaling transduction through the 
Smad-protein (Chen et al., 2004, Miyazono et al., 2005, Nohe et al., 
2004). BMP induced adipogenesis involves both Smad1/5/8 and MAPK 
activation (Hata et al., 2003). BMP induced Smad1/5/8 signaling activates 
PPARγ via zinc finger transcription factor Schnurri-2 and C/EBP𝛼, which 
exhibit adipogenic effects (Krishnan et al., 2006, Takagi et al., 2006). 
Accordingly, a Smad antagonist such as Smad6 reduces both PPARγ 
signaling and BMP-associated adipogenesis (Hata et al., 2003). Similar to 
Smad1/5/8 signaling, BMP induced activation of MAPK signaling is 
associated with PPARγ activation and adipogenic differentiation (Hata et 
al., 2003). Conversely, disruption of MAPK signaling also inhibits both 
PPARγ expression and BMP-associated adipogenesis (Hata et al., 2003). 
Investigators have identified BMP signaling activity at the earliest stages 
of MSC adipogenesis (Bowers et al., 2007, Bowers et al., 2006). When 
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MSCs are forced into a preadipocyte cell lineage through exposure to 5-
azacytidine, a potent inhibitor of DNA methylation, BMP- 4 expression 
increases (Bowers et al., 2007, Bowers et al., 2006). Forced expression of 
BMP-4 in white adipocytes induces a brown adipocyte phenotype, 
including increased energy expenditure and insulin sensitivity (Qian et al., 
2013). Moreover, once MSC have been forced into preadipocyte cells, 
BMP-4 over-expression is sufficient to induce commitment to adipocyte 
lineage differentiation (Kang et al., 2009, Bowers et al., 2007, Ahrens et 
al., 1993). BMP signaling is one of the central signaling pathways 
involved in the induction of osteogenic differentiation and regulation of 
bone formation. Multiple murine studies involving genetically modified 
BMP ligands, BMP receptors, and BMP inhibitors demonstrate a critical 
role for BMP signaling in bone formation (Mishina et al., 2004, Okamoto 
et al., 2006, Gazzerro et al., 2007, Gazzerro et al., 2005). For example, 
transgenic mice with modified BMPR-IA receptors exhibit low bone mass 
and irregular calcification (Mishina et al., 2004). Inhibitors of BMP 
signaling, such as Noggin and Gremlin, impair bone formation when 
overexpressed (Qian et al., 2013, Davis et al., 2007, Zhu et al., 2006). In 
general, BMP induces osteogenesis utilizing both autocrine and paracrine 
pathways (Cheng et al., 2003, Suzawa et al., 1999) and it works in 
conjunction with Osterix through both Runx2-dependent and --
independent pathways. BMP receptor activation in osteogenesis, as well 
as adipogenesis, involves both Smad1/5/8 and MAPK down-stream 
signaling activation. While 31 different BMP ligands are identified to 
date, only some of them actually promote MSC osteogenic differentiation 
(Ducy et al., 2000). Specifically, BMP-2, -4, -6, - 7, and -9 have been 
shown to promote osteogenic commitment, as well as terminal osteogenic 
differentiation in MSC (Kang et al., 2009, Dorman et al., 2012). BMP-2, 
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the most commonly studied BMP ligand, induces MSC osteogenesis both 
in vitro and in vivo (Reid et al., 1982, Varkey et al., 2006, Partirdge et al., 
2002, Wegman et al., 2011, Park et al., 2010, Tang et al., 2008, Kempen 
et al., 2008, Cheng et al., 2001). Furthermore, investigators have found 
that short-term BMP-2 treatment is both necessary and sufficient for 
osteogenic commitment in the murine mesenchymal stem cell line 
C3H10T1/2 (Noel et al., 2004).  
The precise factors that govern BMP signaling-induced adipogenesis 
versus osteogenesis in MSCs are not well understood. Two variables that 
may determine the effects of BMP on MSC differentiation have been 
observed: dosage and receptor type. In terms of dosage, lower 
concentrations of BMP-2 have been shown to favor adipocyte formation, 
while higher concentrations support osteogenic differentiation in 
C3H10T1/2 (Wang et al., 1993). However, these dosage effects may be 
ligand- and cell-type dependent. In terms of receptor type, BMPR-IA 
induces adipogenic effects, while BMPR-1B induces osteogenic effects. 
Even though BMP receptor type and dosage are two known variables that 
affect MSC lineage determination, no global rule applies (Rahman et al., 
2012).  
2.2.4. IGF signaling 
IGF-1 induces its effects through the IGF-I receptor (IGF1R) and IGF-
binding proteins (IGFBPs) 1–6 (Kawai et al., 2009). IGF-1 can be found 
systemically and it is present in most peripheral tissues, including the 
bone (Giustina et al., 2008, Kawai et al., 2009, Govoni et al., 2012). The 
functions of IGF- 1 in bone have been well documented. IGF-1 produces 
its effect by inducing several intracellular signaling pathways. First, IGF-
1 binds to the IGF-1 receptor, which intracellularly autophosphorylates 
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the receptor at the kinase domain. Upon receptor activation, various 
protein substrates are consequently activated, including insulin receptor 
substrate-1 (IRS-1), Src homology and collagen protein (SHC) (Kawai et 
al., 2009). IRS-1 goes on to activate the phospho-inositol 3-kinase (PI3-
K), 3-PI-dependent kinase- (PDK-1), and Akt pathways, while SHC is 
responsible for activating the Ras/Raf/mitogen-activated protein (MAP) 
kinase pathways (Govoni et al., 2012). IRS-1 produces its effect through 
interaction with and activation of PI3K, thereby catalyzing the 
phosphorylation of PIP2 to PIP3. The elevated levels of PIP3 
consequently activate PDK-1 and Akt (Peng et al., 2003). Activation of 
PI3K, PDK-1, and Akt has been shown to be important in skeletal growth 
(Peng et al., 2003, Ghosh-Choudhury et al., 2002). In fact, knockout 
Akt1/Akt2 mice demonstrate significantly impaired bone development 
and skeletal growth (Peng et al., 2003). Meanwhile, SHC, which forms a 
complex with Grb2 and SOC, is responsible for increasing cell 
proliferation through activation of the Ras/Raf-1/MAPK pathway. During 
bone remodeling, IGF-1 is released from the bone matrix to stimulate 
MSC osteoblastogenesis via activation of mammalian Target Of 
Rapamycin (mTOR). This allows for the maintenance of both bone 
structure and mass, both of which were downregulated in mice with 
knockout of IGF- 1 receptors in pre-osteoblastic cells (Xian et al., 2012). 
IGF-1 has been found to promote both adipogenic and osteogenic 
differentiation. For example, IGF-1 induces cell division of adipocyte 
precursor cells (Wabitsch et al., 1995). In addition, IGF receptors are 
involved in promoting adipogenesis through induction of advanced 
glycation end products (AGEs). AGEs activate both NAD(P)H oxidase 
and Src, which ultimately leads to the phosphorylation/activation of both 
IGF-1 receptor and Akt downstream in 3T3-L1 preadipocyte cells (Yang 
  59 
et al., 2013). Further, Akt1/Akt2 knockout mice demonstrate impaired 
adipogenesis (Peng et al., 2003). In fact, it has been shown that both Akt1 
and Akt2 are necessary to induce PPARγ, the key regulator for 
adipogenesis. Thus, a critical threshold of Akt activity, as regulated by 
IGF-1, contributes to the maintenance of cell proliferation, growth, and 
adipogenic differentiation (Peng et al., 2003). In summary, an inverse 
relationship exists between adipogenic and osteogenic lineage 
differentiation in MSCs, which is governed by diverse signaling 
pathways. The understanding of this relationship has far-reaching 
implications for the understanding of human health and treatment of 
human disease.  
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3. Kit 
The viral oncogene v-c-Kit was in 1986 identified as the transforming 
gene of Hardy-Zuckerman 4 feline sarcoma virus (hence its name c-Kit as 
in kitten) (Besmer et al., 1986). It was discovered that Kit is allelic with 
the dominant white spotting locus (W) of mice (Chabot et al., 1988, 
Geissler et al., 1988). Mutations in the Steel (Sl) locus in mice give rise to 
a phenotype very much resembling those of mice with loss-of-function 
mutations in the W locus. Therefore it was soon demonstrated that the 
product of the Steel locus was identical to the ligand for Kit, stem cell 
factor (SCF) (Copeland et al., 1990, Williams et al., 1990).  
Numerous loss-of-function mutations in W and the Sl loci have been 
described in mice. These loci encode Kit and SCF, respectively. These 
naturally occurring mutations comprise a spectrum of defects ranging 
from minor defects in the tyrosine kinase activity of Kit to a complete loss 
of its kinase activity, resulting in the corresponding degree of severity in 
the phenotype displayed by these mice. The expression pattern of Kit and 
SCF during mouse embryogenesis suggests that they are involved in 
migration of cells of the hematopoietic, germ cell, and melanoblast 
lineages, as well as in the differentiation and proliferation of these cells 
(Keshet et al., 1991, Matsui et al., 1990, Or-Urtreger et al., 1990). The 
numerous loss-of-function mutations in this receptor/ligand system 
suggests crucial functions in the hematopoietic system, during gametocyte 
development, pigmentation, intestinal motility, as well as in the nervous 
system (Keshet et al., 1991, Lev et al., 1994, Russel, 1979). Data from 
other models also suggests a function in the immune system, including 
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inflammation (given its expression in both dendritic cells and mast cells) 
and in the regulation of vasculogenesis (reviewed in Heissig et al., 2003, 
Metcalfe, 2008, Ray et al., 2010).  
Cairns et al., (2003) originally identified the cis-acting elements in the 5’ 
flanking region and the first intron of the Kit gene which are essential for 
its expression in hematopoietic progenitors and primordial germ cells 
(PGCs). We found six DNase I hypersensitive sites (HS1-HS6) within 
these genomic regions and developed several mouse lines expressing 
transgenic green fluorescent protein (GFP) under the control of these 
regulatory elements. A construct driven by the Kit promoter and including 
all 6 HS sites was found to be highly expressed during mouse 
development in Kit-expressing cells, including PGCs and hematopoietic 
progenitors. The Kit promoter alone (comprising only HS1) was found to 
be sufficient to drive low-level GFP expression in PGCs, but unable to 
function in hematopoietic cells. Hematopoietic expression further 
required the addition of the intronic HS2 fragment. This intronic fragment 
also greatly potentiated expression of the reporter gene in PGCs. Thus, 
elements within the first intron act as an enhancer in both lineages. 
Optimal hematopoietic expression further required more downstream 
elements within the first intron, which were instead not required for 
expression in PGCs (Cairns et al., 2003). The mouse transgenic lines 
obtained with the constructs containing both the Kit promoter region and 
the first intron were found to express GFP also in postnatal germ cells, 
while those originating from the construct comprising only the promoter 
region expressed low levels of GFP only in PGCs, but not in 
differentiating spermatogonia (Filipponi et al., 2007).  
Cerisoli et al., (2009) reported that this transgene is expressed in the large 
majority of fetal liver and adult bone marrow HSCs. The Kit/GFP 
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transgene appears to be regulated correctly in early Kit+ hematopoietic 
progenitors. In fact, over 90% of cells in bone marrow fractions highly 
enriched in HSC and early progenitor cells, show GFP expression. 
Furthermore, functional HSC are contained within cell fractions that 
express the transgene at intermediate levels, and essentially all the HSC 
capable of long-term reconstitution are in this fraction. In contrast to 
HSC, multipotent and early erythroyd progenitors (CFU-mix and BFU-E) 
express Kit/GFP at high levels. The Kit gene is active in several types of 
stem cells, and its defects affect multiple cell lineages (Broudy, 1997) 
pointing to Kit being a pleiotropic, though cell-type-restricted, molecule. 
It would, therefore, be particularly relevant to have a mouse model in 
which the transgene efficiently recapitulates the activity of the 
endogenous molecule. The currently-used Kit/GFP transgene, in addition 
to being expressed in HSC, in primordial germ cells and subsets of 
spermatogonia (Cairns et al., 2003, Filipponi et al., 2007), is also active in 
a population of cardiac stem cells (Messina et al., 2004). Thus, Kit might 
be regulated by subsets of common transcriptional programs in different 
stem cells. Finally, transgene expression in HSC/progenitors has enabled 
monitoring of bone marrow cells homing to muscle and heart following 
tissue damage (Barile et al., 2011). 
Kit is also involved in melanoblasts development, as it is produced in 
both premigratory and migrating melanocytes. Kit signaling is important 
at several time points also during melanocyte development, and has 
independent effects on both migration and survival along the dorsolateral 
pathway in the embryo (Thomas et al., 2008). 
In addition, a recent work found that positivity to Kit marks a 
subpopulation of human Adipose Stem Cells (ADSCs), which resides in a 
perivascular location, and shows higher proliferative activity and self-
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renewal capacity, higher telomerase activity and expression, higher in 
vitro adipogenic efficiency, a higher capacity for the maintenance of 
cardiac progenitors, and higher pancreatogenic and hepatogenic 
efficiency. Moreover, isolation of Kit positive ADSC subpopulations 
allows for the selection of a more homogeneous subpopulation with 
increased cardioprotective properties and increased adipogenic and 
endodermal differentiation potential, providing a useful tool for specific 
therapies in regenerative medicine applications. (Blazquez-Martinez et al., 
2014). 
The gene for Kit was cloned and found to be located on chromosome 
segment 4q11 in humans (D’Auriol et al., 1988, Yarden et al., 1987) and 
is comprised of 21 exons, spanning more than 34 kb of DNA. The first 
exon encodes the translational initiation codon and the signal peptide. The 
remainder of the extracellular part of Kit is encoded by exons 2–9. The 
transmembrane region is encoded by exon 10, while the remaining exons 
encode the intracellular part of the receptor. Kit expression can be 
regulated by transcription factors, such as Myb and Ets-2 in 
hematopoietic cells. Moreover, Kit has also been reported to be regulated 
by miRNA (miR-193b in leukemic cells (Gao et al., 2011) and mir-221 in 
melanoma cells (Igoucheva and Alexeev, 2009). miR-221 and miR-222 
have been described as regulators of Kit expression in hematopoietic cells 
and have also been reported to be potential regulators of Kit expression in 
gastrointestinal stromal tumors (Felli et al., 2005, Koelz et al., 2011). The 
receptor tyrosine kinase encoded by the Kit gene is a transmembrane 
protein with an extracellular domain made up by five immuno-globulin-
like domains followed by a single spanning transmembrane region. The 
phosphorylation sites, necessary for Kit activity, reside in this 
intracellular region, composed of the juxtamembrane region, and the 
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kinase domains (tyrosine kinase domain 1 and 2) SCF is a homodimer, 
and Kit dimerization is driven by its ability to simultaneously interact 
with two Kit monomers (Lemmon et al., 1997). Furthermore, it was 
proposed that only the first three Ig-like domains were required for SCF 
binding. The first three Ig-like domains in Kit have a complementary 
shape and charge to allow tight binding of SCF, and after binding to each 
other, no major structural changes occur (Yuzava et al., 2007). 
Furthermore, in addition to bringing two Kit monomers together into a 
dimeric complex, ligand binding also induces a conformational change 
that enables homotypic interactions between Ig-like domains 4 and 5 in 
two adjacent Kit molecules (Yuzava et al., 2007).  There are many signal 
transduction downstream of Kit, such as the PI3-kinase, Src family 
kinases, MAPK pathways, and phospholipases. These pathways are 
integrated into a signaling circuit.  Autophosphorylated receptors interact 
with the Src homology 2 (SH2) domains of the p85 subunit (p85α︎, p50α︎, 
p55α︎, p85β, and p55γ), resulting in a conformation change in the 
associated enzymatic p110 subunit (p110α︎, p110β, and p110δ), which 
leads to its activation (Klippel et al., 1994). PI3-kinase is activated by 
SCF through direct binding to Tyr-721 (Lev et al., 1992, Serve et al., 
1994). Akt is a key molecule downstream of PI3-kinase that promotes cell 
survival by interfering with the initiation of apoptosis (Datta et al., 1997). 
 The serine/threonine kinase Akt is located downstream of PI3-kinase and 
is a molecule in survival signaling in response to SCF.  Activated Akt 
promotes cell survival in different ways including phosphorylation of 
Bad, Foxo, and activation of nuclear factor kappa-light chain enhancer of 
activated B cells (NF-kB). Bad is a protein involved in the control of 
cytochrome c release from the mitochondria, an initial event in the 
activation of the caspase cascade. In the absence of survival signals, Bad  
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Figura 6. Schematic representation of SCF-induced Kit-activation (Lennartsson and 
Ronnstrand, 2012) 
heterodimerizes and thereby neutralizes the anti-apoptotic proteins Bcl-XL 
or Bcl-2 (Yang et al., 1995). In response to SCF treatment, Akt is 
activated in a PI3-kinase-dependent manner resulting in Bad 
phosphorylation on Ser-136 (Blume-Jensen et al., 1998), which disrupts 
the interaction between Bad and Bcl-XL. Bad is sequestered by 14–3-3 
proteins (Zha et al., 1996). Bcl-XL can then antagonize the pro-apoptotic 
Bax protein in a manner blocking cytochrome c release and consequently 
apoptosis.  It has also been found that melanocyte proliferation and 
migration in response to SCF stimulation was dependent on PI3-kinase 
(Jeon et al., 2009).  The Src family of tyrosine kinases (SFK) contains 
eight cytoplasmic kinases, some of which are ubiquitously expressed (Src, 
Yes, and Fyn), whereas others have more restricted, often hematopoietic 
expression (Lck, Hck, Lyn, Fgr, and Blk).  In response to SCF 
stimulation, Kit becomes phosphorylated on two residues in the 
juxtamambrane region (Tyr-568 and Tyr-570) (Krystal et al., 1998, 
Lennartsson et al., 1999, Linnekin et al., 1997, Price et al., 1997). These 
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phosphorylation sites interact with the SH2 domain in SFK (Lennartsson 
et al., 1999). Activated SFK have been shown to contribute to activation 
of several signal pathways downstream of Kit. Several groups have 
implicated SFK in SCF-induced ERK1/2 mitogen-activated protein 
(MAP) kinase activation (Bondzi et al., 2000, Lennartsson et al., 1999), 
possibly by promoting the phosphorylation of the Shc adaptor protein 
(Lennartsson et al., 1999). The JNK MAP kinase pathway is activated by 
Kit in a manner that requires both SFK and PI3-kinase acting on Rac1 
(Timokhina et al., 1998).  Several studies have implicated activation of 
SFK in Kit-induced proliferation.  Activation of Kit protects many cells 
from apoptosis; this effect has to a large extent been ascribed to PI3-
kinase signaling. However, SFK also contributes to the survival effect. 
Treatment of erythroid precursor cells with SCF is able to suppress Fas-
mediated apoptosis, and this effect was abolished by the SFK inhibitor 
PP2 (Nishio et al., 2001). In mast cells, both SFK and PI3-kinase were 
shown to be important for SCF-mediated protection form apoptosis 
(Timokhina et al., 1998). SFK have also been implicated downstream of 
Kit in promoting cell migration. MAP kinases are activated downstream 
of most types of cell surface receptors and hence play central roles in a 
multitude of biological processes, both under normal and pathological 
conditions. The MAP kinase pathway has the architecture of a three-
layered kinase module that is initiated at the plasma membrane and 
reaches to the nucleus where it regulates gene expression often by 
phosphorylating transcription factors. However, also processes occurring 
in the cytoplasm, for example, translation and cell migration can be 
regulated by MAP kinases. The biological consequence of MAP kinase 
activation is connected to the magnitude as well as the duration of MAP 
kinase phosphorylation (Marshall et al., 1995, Yamamoto et al., 2006). 
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All eukaryotic cells have at least one type of MAP kinase and human cells 
contain four major groups: ERK1 and -2 (ERK1/2), ERK5, p38, and JNK. 
 Stimulation of Kit has been shown to activate ERK1/2, p38, JNK, and 
ERK5,  Several studies have implicated p38 in the signaling circuitry 
regulating cell migration, and inhibition of p38 inhibits this pathway 
(Kuang et al., 2008, McDaniel et al., 2008, Sundstrom et al., 2001). Ueda 
et al., (2002) found that SCF-induced p38 and PI3-kinase activation was 
important for Ca2 influx, which in turn activated ERK1/2, and promoted 
cell migration.  
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4. Prep1 
The TALE subfamily (Three Aminoacids Loop Extension) of homeobox 
genes, encode transcription factors that have a broad spectrum of 
functions both in embryonic development and in adult stem and 
progenitor cell. Prep1 is a member of TALE proteins and interestingly, 
even small variations in its expression level can have dramatic effects in 
murine embryonic development, suggesting that different threshold levels 
are required for distinct Prep1 functions.  
Prep1 forms DNA-independent dimeric complexes with all isoforms of 
the Pbx homeodomain transcription factor, enhancing target specificity 
and regulating their activity, nuclear localization, and likely, function in 
development (Berthelsen et al., 1998, Calvo et l., 1999, Knoepfler et al., 
1997, Pai et al., 1998, Rieckhof et al., 1997).  
Prep1 deficiency affects the expression of both TALE class partners Pbx 
and Meis, and the decrease of Prep1, Pbx and Meis proteins in Prep1i/i 
embryos almost abolishes the DNA-binding activity of Meis/Prep-Pbx 
dimer-specific target sequences. As the mRNA levels of these proteins are 
not affected in a statistically significant manner, their reduction appears to 
be at the post-transcriptional level. In mammalian cells in culture, Prep1 
overexpression does not affect Pbx1 and Pbx2 mRNA levels, but 
increases the stability of Pbx1 and Pbx2 by preventing their proteasomal 
degradation (Longobardi and Blasi, 2003). As a result, in the absence of 
Prep1, Pbx proteins are not protected from proteasomal degradation. 
However, Prep1 deficiency results in a decrease of Pbx3, Pbx4, Meis2, 
and Meis3 mRNAs in whole E10.5 embryos. Thus, Prep1 not only forms 
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transcriptional complexes with Pbx but also hierarchically controls the 
expression of all Pbx and Meis genes.  Mammals have two Prep genes, 
Prep1 and Prep2 (Berthelsen et al., 1998 Fognani et al., 2002, Haller et 
al., 2002), while zebrafish have three, prep1.1, prep1.2, and prep2 (De 
Florian et al., 2004). Down-regulation with morpholino antisense 
oligonucleotides of the prep1.1 gene in zebrafish causes an embryonic 
lethal phenotype with extensive brain apoptosis, loss of hindbrain 
rhombomeric segmentation, lack of cartilage differentiation of neural 
crest cells, pericardial edema, and lack of fins (De Florian et al., 2004). 
 In mice, a null Prep1 mutation results in early lethality (E7.5), precluding 
further studies of Prep1 in later developmental stages.  Thus, in order to 
understand the in vivo role of Prep1 during adulthood, an embryonic 
lethal hypomorphic mutant mouse (Prep1i/i) was generated. An insertion 
of a retroviral vector in the first intron of the Prep1 gene (Prep1i/i) results 
in a hypomorphic mutation that exhibits variable penetrance and various 
levels of expression (Penkov et al., 2005). Prep1 deficiency manifests 
with different degree of severity, depending on the level of expression. 
Prep1 null embryos die at E7.5, while hypomorphic Prep1i/i mutation 
cause embryonic lethality with variable penetrance. The majority of 
Prep1i/i embryos die of anemia at E17.5–P0, showing a more severe 
phenotype when lower levels of Prep1 are produced. These mice are 
characterized by an overall organ hypoplasia, severe anemia, impaired 
angiogenesis, and eye anomalies, particularly in the lens and retina. The 
ability of one quarter of these embryos to survive and live at least 16–18 
months (Ferretti et al., 2006) is likely due to residual expression of low 
levels of Prep1. This suggests that different Prep1 threshold levels are 
required at different stages of the embryonic development. The Prep1i/i 
embryonic phenotype recapitulates other TALE family members 
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phenotypes, such as Meis1 and Pbx1.  The Pbx family comprises four 
genes in mammals which are differentially expressed during embryonic 
development and in the adult (Ferretti et al., 1999, Monica et al., 1991). 
Pbx1-deficient mice exhibit an embryonic lethal phenotype, characterized 
by homeotic transformation of elements of the second branchial arch and 
by defective organogenesis affecting the spleen, pancreas, kidney, and 
organs of the caudal pharyngeal pouches (Kim et al., 2002, Manley et al., 
2004, Schnabel et al., 2003, Selleri et al., 2001). Pbx1-deficient embryos 
also show defective definitive hematopoiesis (Dimartino et al., 2001) and 
are unable to induce splenic cell fate specification during early 
embryogenesis (Brendolan et al., 2005).  Meis1, Meis2, and Meis3 form 
transcriptionally active complexes with Pbx, that have an important role 
during embryonic development (Berthelsen et al., 1998, Chang et al., 
1997, Ferretti et al., 1999, Knoepfler et al., 1997, Kurant et al., 1998, 
Salzburg et al., 1999, Vlachakis et al., 2001, Waskiewicz et al., 2001). 
Meis/Prep-Pbx complexes, in turn, bind to and modify the activity of 
other proteins, such as the Hox proteins Hoxb1, Hox11, Pdx1; and other 
transcription factors such as MyoD (Berkes et al., 2004, Brendolan et al., 
2005, Ferretti et al., 2000, Jacobs et al., 1999, Ryoo et al., 1999, Thomas 
et al., 2005). Meis/Prep-Pbx complexes control expression of numerous 
genes, including Hoxb1, Hoxb2, Hoxa3, Hox11, and glucagon (Brendolan 
et al., 2005, Ferretti et al., 2000, Herzig et al., 2000, Jacobs et al., 1999, 
Manzanares et al., 2001, Ryoo et al., 1999, Salzburg et al., 1999.  Meis1-
deficient mice exhibit an embryonic lethal phenotype (E13.5 to 14.5) with 
major defects in hematopoiesis, angiogenesis, and eye formation 
(Azcoitia et al., 2005, Hisa et al., 2004), while Meis2 appears to be 
involved in controlling limb outgrowth (Capdevila et al., 1999, Mercader 
et al., 2005).  By using Prep1 hypomorphic mice, it has been possible to 
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study Prep1 role and consequently establish that Prep1 is a master gene 
required for hematopoietic, angiogenic, and eye development, as well as 
other developmental functions, by controlling the levels of Pbx and Meis 
TALE proteins and their target genes. Many of the phenotypes observed 
in Prep1i/i embryos may be mediated by the concomitant loss of Meis and 
Pbx partners, therefore resulting in defects closely resembling those of 
Pbx1 and Meis1 null embryos. 
 
Prep1 is required for the lymphoid as well as the erythroid lineages. The 
hematopoietic phenotype is characterized by a drastic decrease in the 
number of circulating erythrocytes and a delay in erythroid 
differentiation. E15.5-E16.5 Prep1i/i fetal livers (FL) contain more 
erythroid progenitors and fewer erythroid differentiated cells (Ferretti et 
al., 2006), as compared to their wild type counterpart. One of the genes 
required for normal erythropoiesis is cMyb. FLs from Prep1i/i embryos 
exhibit a drastic decrease in cMyb-positive cells. Therefore, the overall 
decrease in cMyb levels can, at least in part, explain the erythroid 
phenotype (Emambokus et al., 2003).  Prep1i/i hypomorphic embryos are 
also deficient in B-lymphoid differentiation. Prep1i/i FL cells fail to 
compete with wild type cells in competitive repopulation assays, in 
essentially all hematopoietic lineages. Prep1 is expressed in KSLA and B-
cells progenitors, and in cells that coexpress markers of hematopoietic 
stem/progenitors cells. these data suggestthat in the absence of proper 
levels of Prep1 active long-term repopulating hematopoietic stem cells 
(LTR-HSC) are decreased in activity and/or in number. Prep1i/i embryos 
display a major FL hypoplasy which affects the number of KSLA cells, 
highly enriched in LTR-HSC cells (Hsu et al., 2000). When analyzed in 
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detail, Prep1i/i FL cells show a deficient proliferation of myeloid 
progenitors (CFU-GEMM) colonies in methylcellulose, furthermore 
Prep1i/i FL cells have a tendency to show delayed or blocked 
differentiation of the B-lymphocytes precursors (Di Rosa et al., 2007). 
Therefore, Prep1 expression is required for the proper functioning of the 
embryonic hematopoietic system. 
Prep1 has is expressed in adult hematopoietic cells, namely in the BM 
Lin-Sca+ population. After birth, the hypomorphic mice which escape 
embryonic lethality, exhibit a defect in T-cell differentiation, with a 
decreased number of circulating CD4+ and CD8+T cells, increased 
apoptosis, and decreased proliferation of double-positive thymocytes; 
anomalies in T-cell receptor expression, a phenotype reproduced in wt 
mice transplanted with Prep1i/i FL cells (Penkov et al., 2005).  The 
hematopoietic phenotypes of the Meis1 knock-out and the Prep1i/i 
hypomorphic embryos are very similar (deficient hematopoiesis, 
angiogenesis and oculogenesis) (Hisa et al., 2004; Azcoitia et al., 2005; 
Ferretti et al., 2006). Since Prep1 controls the level of all Pbx and Meis1 
(Ferretti et al., 2006), the Prep1i/i phenotype likely depends, at least 
partially, on the reduction of Pbx and Meis1. However, while Pbx1 was 
shown to be required for B-lymphoid differentiation at a stage lying 
between the hematopoietic stem cells and the pro-B progenitors (Sanyal et 
al., 2007), low levels of Prep1 appear to affect not only the differentiation 
of B-cell progenitors, but also of precursors, possibly including the LTR-
HSC.  Prep1 is an important player in the activity of LTR-HSC and in the 
differentiation of various progenitor lineages. Prep1 not only directly 
participates in this pathway by dimerizing with Pbx but also controls the 
expression of Pbx and Meis, and hence it should also affect the activity 
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and expression of Hox and other genes regulating differentiation.  A 
recent work has shown that Prep1 controls both the number and the 
function of HSCs during mouse embryo development. Prep1 regulates 
HSCs self-renew since its hypomorphic cells are deficient in being able to 
generate generating proper stem cell compartment upon transplantation 
into ablated hosts, and undergo faster exhaustion upon serial 
transplantation. Prep1 maintains FL HSCs in G0 phase. It is known that 
FL HSCs are mainly proliferating cells as compared to the quiescent adult 
BM HSCs (qui puoi mettere Ye et al¨). In homeostatic conditions BM 
HSCs divide preferentially by asymmetric cell division, in order to give 
rise to mature cells and maintain the stem cell pool. In contrast, FL HSCs 
are characterized by symmetric self renewing divisions in order to expand 
the stem cell pool. Prep1 deficiency brings to a reduction in FL HSC 
numbers which favours an increase in multipotent progenitor cells. Prep1 
mutation results in a disequilibrium between stem cells and progenitors, 
due to a change in the balance between asymmetric and symmetric cell 
divisions inclined to the asymmetric one, leading to a reduction of the 
stem cell pool and an increase of the progenitor compartment (Modica et 
al., 2014). This phenotype is consistent with the effects exhibited by Pbx 
and Meis1 null HSCs. However while Pbx1 and Meis1 act on TGFβ 
response, Prep1 is implicated in the regulation of the Interferon(IFN)-
response pathway, which has been shown to regulate HSCs properties in 
both adult and fetal tissues. In particular, IFNα induces adult HSCs 
proliferation, concomitantly to decreasing their G0 pool, leading to HSCs 
exhaustion (Di Rosa et al., 2007).  
 
Angiogenesis is also impaired in Prep1i/i embryos. E7.5-7.75 Prep1i/i 
allantois preparations and E10.5 whole embryos show indeed reduced, 
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thinner, and less-organized capillaries. Angiogenic precursors are also 
affected by Prep1 deficiency. In fact, Prep1 is present in endothelial 
precursors, where it colocalizes with their markers CD31 and c-Kit in 
E14.5 FL. Furthermore, the finding of a decreased microvasculature in 
Prep1i/i allantois cultures indicates that Prep1i/i embryos have an intrinsic 
angiogenic defect, which does not simply reflect a decrease in circulating 
blood cells, and thus is independent from the hematopoietic phenotype 
(Ferretti et al., 2006).  
 
Another frequent phenotype of Prep1i/i embryos involved eye 
development. In most cases, the size of the lens is strongly reduced, 
similar to the phenotype of Pax6-deficient mice, where no lens induction 
and anomalies of the neural retina have been reported (Simpson et al., 
2002, Treisman et al., 2004). Prep1 is present in E14.5 neural retina, 
cornea, and lens epithelium and specifically colocalized with Pax6.  Pax6 
is essential for oculogenesis and it is dramatically reduced in Prep1i/i 
embryos, thus explaining the eye phenotype in these mutant mice 
(Gehring et al., 1999, Lang, 2004, Simpson and Pryce, 2002, Treisman, 
2004).  Moreover, previous biochemical and genetic data demonstrate that 
Meis1 directly regulates Pax6 expression during vertebrate lens 
morphogenesis (Zhang et al., 2002). As Prep1i/i embryos exhibit also 
lower levels of Meis1 protein, the Prep1i/i ocular phenotype might be due 
to reduced Meis1 expression. The angiogenic, hematopoietic, and eye 
phenotypes have also been reported in Meis1-deficient embryos (Azcoitia 
et al., 2005, Hisa et al., 2004). As Prep1 and Meis act by dimerizing with 
Pbx proteins, it is possible that Pbx also participates in the regulation of 
Pax6 expression and eye development.  
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After examination of glucose homeostasis in Prep1i/i mice it was clear that 
an absolute reduction in circulating insulin levels but normal glucose 
tolerance occur. In addition, these mice are protected from streptozotocin-
induced diabetes and enhanced insulin sensitivity with improved glucose 
uptake and insulin-dependent glucose disposal by skeletal muscle 
(Oriente et al., 2008).  p160 Myb-binding protein (p160) (Tavner et al., 
1998) is a repressor of the regulator of glucose and energy metabolism, 
PPAR-gamma coactivator-1α (PGC-1α) (Fan et al., 2004), and 
interestingly, a direct Prep1-interacting protein that competes with Pbx1 
for Prep1 binding (Diaz et al., 2007). Thus, Prep1 functions may depend 
not only on its interaction with Pbx but also with p160. It has been shown 
that there is a balance between p160-Prep1 and Pbx1-Prep1 complexes; 
when p160 levels exceed Pbx1 levels, p160 binds Prep1, which is 
stabilized, and represses GLUT4 and insulin sensitivity. When Pbx1 is 
present in excess, the reverse occurs.  In Prep1i/i muscle, there are normal 
levels of Pbx1 but reduced levels of p160. Decreased levels of p160 lead 
to a muscle-selective increase in mRNA and protein levels of PGC-1α, 
accompanied by enhanced expression of the GLUT4 transporter, 
responsible for insulin-stimulated glucose uptake in muscle. Thus, Prep1 
controls the stability of the p160 protein and, as a consequence, it controls 
insulin sensitivity through the p160-GLUT4 pathway (Oriente et al., 
2008).  
 
Several studies support the idea that Prep1 has also a role in maintaining 
genomic stability and preventing neoplastic transformation.  The DNA-
protecting role of Prep1 may be essential during embryonic development 
already at the epiblast stage, when Prep1 null embryos die (Fernandez-
Diaz et al., 2010). Several crucial events take place during early 
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development. In the E3.5 blastocyst, the inner cell mass (ICM) contains 
progenitor cells, including epiblast (Epi) precursors (Chazaud et al., 
2006), which generate embryonic stem (ES) cells (Evans and Kaufman, 
1981; Martin, 1981).  The Epi is established during implantation around 
E4.5, and from E5.5 to E6.5 forms an epithelium, maintains its 
pluripotent state (Niwa, 2007) and actively proliferates. At this time, the 
Epi is very sensitive to DNA damage (Heyer et al., 2000) and is not 
protected by the usual G1 and G2 check points (O’Farrell et al., 2004). 
DNA damage at this stage leads to p53-dependent apoptosis (Heyer et al., 
2000). The absence of Prep1 causes p53-dependent apoptosis in Epi cells, 
which prevents gastrulation and differentiation. This is probably due to 
the accumulation of DNA damage (Fernandez-Diaz et al., 2010). The 
absence of Prep1 affects all cells but apoptosis is mostly observed in the 
Epi, probably owing to the strong proliferative expansion of these cells at 
such stage. Thus, one of the roles of Prep1 in early embryogenesis is to 
protect epiblast cells from accumulating damage that induces apoptosis 
(Fernandez-Diaz et al., 2011). 
 
Genetic instability is a common feature in cancer and, in fact, mutations 
in genes involved in processes like DNA repair, chromosomal 
segregation, checkpoint control, and centrosome duplication are 
oncogenic (Lengauer et al., 1998, Negrini et al., 2010). Many tumor 
suppressor genes are specialized in controlling these processes.  Prep1i/i 
hypomorphic mice that escape embryonic lethality, develop spontaneous 
tumors or pre-tumoral lesions, and transplantation of Prep1i/i fetal liver 
(FL) cells into lethally irradiated normal mice induces lymphomas. Prep1 
is absent or strongly down-regulated in about 70% of 700 human cancers. 
This evidence indicates that Prep1 is a novel tumor suppressor gene 
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(Longobardi et al., 2010). Interestingly, a recent study has demonstrated 
that the key feature of Prep1 tumor-inhibiting activity is the control of the 
oncogene Meis1 stability. Prep1 post-translationally controls the level of 
Meis1, decreasing its stability by sequesterin Pbx1 (Dardaei et al., 2014).  
Moreover, Iotti et al., (2011) show that the tumor suppressor Prep1 
(Longobardi et al., 2010) prevents genetic instability. Indeed, 
hypomorphic Prep1i/i FL cells and mouse embryonic fibroblasts (MEFs) 
exhibit increased basal DNA damage and normal DNA damage response 
after γ-irradiation, as compared to wt counterparts. Cytogenetic analysis 
shows the presence of numerous chromosomal aberrations and aneuploidy 
at early-passage Prep1i/i MEFs. In human fibroblasts, Prep1 down-
regulation by siRNA induces DNA damage response, similarly to Prep1i/i 
MEFs, together with an increase in heterochromatin-associated 
modifications: rapid increase of histone methylation and decreased 
transcription of satellite DNA. Ectopic expression of Prep1 rescues DNA 
damage and heterochromatin methylation. Finally, Prep1 deficiency 
facilitates cell immortalization, and escape from oncogene-induced 
senescence. These results show that the tumor suppressor role of Prep1 is 
associated with the maintenance of genomic stability (Iotti et al., 2011).  
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5. Aim of the project 
MSCs, for their biological properties, represent a potentially precious 
therapeutic tool in regenerative medicine, for a wide spectrum of 
pathologies. Their clinical use is of particular interest in the fields of 
orthopedic surgery, metabolic disorders and bone marrow transplantation. 
However, their optimal use depends on our knowledge of their biology, 
and the identification of signalling pathways that regulate their expansion 
and differentiation, still poorly understood. In addition, MSCs and their 
progeny, in particular osteoblasts, are essential components of the 
Hematopoietic Stem Cells (HSCs) niche, which provide the appropriate 
microenvironment for engrafment, survival, migration, growth, and 
differentiation. Interestingly, in the bone marrow, MSC differentiation 
towards the osteogenic or the adipogenic lineage is competitively 
balanced and mechanisms that promote one cell fate actively suppress 
molecular regulators that induce the alternative cell program. This fine 
control is based on the cross talk between complex signaling pathways. 
Much efforts has been made to understand molecular mechanisms driving 
differentiation from progenitors to terminal differentiated cells, taking 
advantage of pre-adipocytes and pre-osteblasts cell line. However, little is 
known yet about the molecular mechanisms driving the initial 
commitment phase towards the adipogenic or the osteogenic fate, likely 
working as a switch. In our laboratory we hypothesized that key 
regulatory genes of hematopoietic stem and progenitor cells might 
mediate the cross talk between mesenchymal and hematopoietic cells.  
My thesis is aimed at investigating the role that the Stem Cell Factor 
receptor kit and the transcrition factor Prep1 may play in the regulation of 
  79 
MSCs. The rationale for choosing Kit is: i. it is a “stem cell gene” 
involved in survival, proliferation, and migration of hematopoietic, 
cardiac and neural stem and progenitor cells, melanoblasts and Primordial 
Germ Cells; ii. it has been extensively studied by our group (Cairns et al., 
2003, Cerisoli et al., 2009, Barile et al., 2011), using a Kit/GFP transgenic 
mouse line in which the expression of the transgene recapitulates the 
activity of the endogenous gene in various types of stem and progenitor 
cells; the role of Kit in the control of the MSCs is still controversial. The 
rationale for studying Prep1 is: i. also this transcription factor of the 
TALE family has pleiotropic effects in multiple tissues; ii. it plays a 
pivotal role in the regulation of hematopoietic stem and/or progenitor 
cells and it is not clear yet whether the altered hematopoietic 
compartment shown by Prep1 hypomorphic mice is due to a cell 
autonomous or non cell autonomous defect. (Penkov et al., 2005, Ferretti 
et al., 2006, Di Rosa et al., 2007). 
Real time qPCR, FACS and Western Blot analysis are initially performed 
to analyze Kit and Prep1 expression, both at the mRNA and protein level, 
in undifferentiated culture and during in vitro adipogenic and osteogenic 
processes. Furthermore, functional studies by using a Prep1 hypomorphic 
(Prepi/i) murine line allow to address the effects of Prep1-deficiency in 
undifferentiated cells and after adipogenic and osteogenic induction. 
  
